NZ711659B2 - Therapeutic uses of empagliflozin - Google Patents

Abstract

The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. In a preferred embodiment the invention relates to the use of empagliflozin to reduce the risk of cardiovascular death and/or heart failure requiring hospitalisation in patients with type 2 diabetes. 1 or type 2 diabetes patients. In a preferred embodiment the invention relates to the use of empagliflozin to reduce the risk of cardiovascular death and/or heart failure requiring hospitalisation in patients with type 2 diabetes.

Description

THERAPEUTIC USES OF EMPAGLIFLOZIN Technical Field of the Invention The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 es mellitus, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for e type 1 or type 2 diabetes mellitus patients. The t invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the ence of a vascular event in patients, for example patients with type 1 or type 2 diabetes us.

Background of the Invention The rising prevalences of type 2 es mellitus (T2DM) represent major challenges for global public health. ide, there are more than 220 million ts with type 2 diabetes mellitus, figures which are projected to rise by 2030 (World Health Organisation 2010; International Diabetes Federation 2010). According to the US Centers for Disease Control and Prevention, rates of type 2 diabetes mellitus have tripled in the past 30 years. Diabetes now affects an estimated 23.6 n people in the United States; another 57 n have betes. Prediabetes raises short-term absolute risk of type 2 diabetes mellitus five- to sixfold.

Type 2 diabetes mellitus is an increasingly prevalent disease that due to a high frequency of complications leads to a significant ion of life expectancy. Because of diabetes- associated microvascular complications, type 2 diabetes is currently the most frequent cause of adult-onset loss of vision, renal failure, and amputations in the industrialized world. In addition, the presence of type 2 diabetes mellitus is associated with a two to five fold increase in cardiovascular e risk.

After long duration of disease, most patients with type 2 diabetes mellitus will eventually fail on oral therapy and become insulin dependent with the necessity for daily injections and multiple daily glucose measurements.

The UKPDS (United Kingdom ctive Diabetes Study) demonstrated that intensive treatment with metformin, sulfonylureas or insulin resulted in only a limited improvement of glycemic control (difference in HbA1c ~0.9%). In addition, even in patients within the W0 2014/161918 _ 2 _ intensive treatment arm glycemic control orated significantly over time and this was attributed to deterioration of B-cell function. Therefore many ts with type 2 diabetes me||itus remain uately d, partly because of limitations in long term efficacy, tolerability and dosing inconvenience of existing antihyperglycemic ies.

Oral abetic drugs conventionally used in therapy (such as eg. first- or -line, and/or mono- or (initial or add-on) combination therapy) include, without being restricted thereto, metformin, sulphonylureas, thiazolidinediones, glinides, DPP-4 inhibitors and or- glucosidase inhibitors.

The high incidence of therapeutic failure is a major contributor to the high rate of long-term hyperglycemia-associated complications or chronic s (including micro- and macrovascular complications such as eg. diabetic phathy, retinopathy or neuropathy, or cardiovascular complications) in patients with type 2 diabetes me||itus.

Therefore, there is an unmet medical need for methods, medicaments and pharmaceutical compositions with a good efficacy with regard to ic control, with regard to disease- modifying properties and with regard to reduction of cardiovascular morbidity and mortality while at the same time showing an improved safety profile.

Summary of the Invention The present invention s to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in ts with type 1 or type 2 diabetes me||itus. The present invention also relates to the use of such SGLT-2 inhibitors in the treatment and/or prevention of cardiovascular diseases in patients, for example in type 1 or type 2 diabetes me||itus patients. The present invention also s to the use of such SGLT-2 inhibitors in treatment and/or prevention of a metabolic disorder in patients with or at risk of cardiovascular disease.

The present invention further relates to n SGLT-2 inhibitors for ng and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for e patients with type 1 or type 2 diabetes me||itus. The present invention also further relates to certain SGLT-2 inhibitors for preventing, g, delaying or treating the degeneration of pancreatic beta cells and/or the decline of the functionality of pancreatic beta cells and/or for improving and/or restoring the functionality of pancreatic beta cells and/or restoring the functionality of pancreatic insulin secretion in patients having latent autoimmune diabetes in adults (LADA).

In one embodiment, the present invention provides a method for treating and/or preventing oxidative stress, vascular stress and/or elial ction comprising administering empagliflozin, optionally in combination with one or more other therapeutic substances, to a t in need thereof. In one embodiment, the patient is a non-diabetic patient or a patient with type 1 or type 2 diabetes mellitus. In one embodiment, the method is for treating and/or preventing endothelial dysfunction in a patient with type 1 or type 2 diabetes mellitus.

In one embodiment, the present invention provides a method for treating and/or preventing collagen deposition and/or vessel wall thickening comprising administering empagliflozin, optionally in combination with one or more other therapeutic substances, to a patient in need thereof. In one embodiment, the patient is a abetic patient or a patient with type 1 or type 2 diabetes mellitus. In one embodiment, the method is for treating and/or preventing elial dysfunction in a patient with type 1 or type 2 diabetes mellitus.

In one embodiment, the present invention provides a method of treating type 2 diabetes mellitus in a t with or at risk of oxidative stress, ar stress and/or endothelial dysfunction, or diseases or conditions related or associated therewith, said method comprising stering empagliflozin, optionally in combination with one or more other therapeutic nces, to the patient.

In one embodiment, the present invention provides a method for using empagliflozin in one or more of the following methods: - preventing, slowing the progression of, delaying or treating a metabolic disorder selected from the group consisting of type 1 or type 2 diabetes mellitus, impaired glucose tolerance, impaired fasting blood glucose, hyperglycemia, postprandial hyperglycemia, hyperinsulinemia and metabolic syndrome; or - g the ssion of, ng or treating of pre-diabetes; or - preventing, slowing the progression of, delaying or treating of an onset of type 2 diabetes mellitus; or - improving glycemic control and/or for reducing of fasting plasma e, of postprandial plasma glucose and/or of ylated hemoglobin HbA1c; or - preventing, slowing, delaying or reversing progression from impaired glucose nce, impaired fasting blood glucose, n resistance or from metabolic syndrome to type 2 diabetes mellitus; or W0 2014/161918 _ 4 _ - preventing, slowing the progression of, delaying or treating of a ion or disorder selected from the group consisting of complications of diabetes mellitus such as cataracts and micro- and macrovascular diseases, such as nephropathy, retinopathy, athy, tissue ischaemia, diabetic foot, dyslipidemia, arteriosclerosis, myocardial tion, accute coronary syndrome, unstable angina pectoris, stable angina pectoris, stroke, peripheral arterial occlusive disease, cardiomyopathy, heart failure, heart rhythm ers and vascular restenosis; or - reducing body weight and/or body fat, or preventing an increase in body weight and/or body fat, or facilitating a reduction in body weight and/or body fat; or - preventing, slowing, delaying or treating the degeneration of pancreatic beta cells and/or the decline of the functionality of pancreatic beta cells and/or for improving and/or restoring the functionality of pancreatic beta cells and/or restoring the functionality of atic insulin secretion; or - preventing, slowing, delaying or treating diseases or conditions attributed to an abnormal accumulation of ectopic fat, in particular liver fat; or - for maintaining and/or improving the insulin sensitivity and/or for treating or ting nsulinemia and/or insulin resistance; in a patient with or at risk of oxidative stress, ar stress and/or endothelial dysfunction, or diseases or conditions related or associated ith, or in a patient with or at risk of cardiovascular disease selected from myocardial infarction, stroke, peripheral arterial occlusive e, or in a patient with one or more vascular risk factors ed from A), B), C) and D): A) previous or existing vascular disease selected from myocardial infarction, coronary artery disease, percutaneous coronary intervention, coronary artery by-pass grafting, ic or hemorrhagic stroke, congestive heart failure, and peripheral occlusive arterial disease, B) advanced age >/= 60-70 years, and C) one or more cardiovascular risk factors selected from - ed type 1 or type 2 diabetes us > 10 years duration, - hypertension, - current daily cigarette smoking, - dyslipidemia, - obesity, - age >/= 40 - metabolic syndrome, hyperinsulinemia or insulin ance, and - hyperuricemia, erectile dysfunction, polycystic ovary syndrome, sleep apnea, or family history of vascular disease or cardiomyopathy in first-degree relative; D) one or more of the following: - confirmed history of myocardial infarction, - unstable angina with nted multivessel coronary disease or positive stress test, - multivessel Percutaneous Coronary ention, - multivessel Coronary Artery By-pass Grafting (CABG), - history of ischemic or hemorrhagic stroke, - peripheral occlusive arterial disease. said method comprising administering empagliflozin, optionally in combination with one or more other therapeutic substances, to the patient.

In one ment, the method comprises treating type 1 or type 2 diabetes mellitus. In one embodiment, the patient is a type 1 or type 2 diabetes mellitus patient with or at risk of a cardiovascular disease selected from myocardial infarction, stroke, peripheral arterial occlusive diasease.

In one embodiment, the patient is a patient with type 1 or type 2 diabetes mellitus or with pre- diabetes with one or more cardiovascular risk factors selected from A), B), C) and D): A) previous or ng vascular disease selected from myocardial infarction, ry artery e, percutaneous coronary intervention, coronary artery by-pass ng, ischemic or hemorrhagic stroke, congestive heart failure, and peripheral occlusive arterial disease, B) ed age >/= 60-70 years, and C) one or more cardiovascular risk factors selected from - advanced type 1 or type 2 diabetes mellitus > 10 years duration, - hypertension, - current daily cigarette g, - dyslipidemia, - obesity, - age >/= 40, - metabolic syndrome, hyperinsulinemia or insulin resistance, and - hyperuricemia, erectile dysfunction, polycystic ovary syndrome, sleep apnea, or family history of vascular e or cardiomyopathy in first-degree relative; D) one or more of the following: - confirmed history of myocardial infarction, - le angina with documented multivessel coronary disease or ve stress test, - multivessel Percutaneous Coronary Intervention, W0 2014/161918 _ 6 _ - multivessel Coronary Artery By-pass Grafting (CABG), - history of ischemic or hemorrhagic stroke, - eral occlusive arterial disease.

In another embodiment, the present invention provides a method of preventing, reducing the risk of or delaying the ence of a cardiovascular event in a patient with type 1 or type 2 diabetes mellitus or with pre-diabetes, said method comprising administering iflozin, optionally in combination with one or more other therapeutic nces, to the t. In one embodiment, the cardiovascular event is ed from cardiovascular death, non-fatal myocardial infarction, tal stroke, hospitalisation for unstable angina pectoris and heart failure requiring hospitalisation. In one embodiment, the vascular death is due to fatal myocardial infarction or fatal stroke. In one embodiment, the patient has or is at risk of a cardiovascular disease.

In one ment, the patient with type 1 or type 2 diabetes mellitus or with pre-diabetes has one or more cardiovascular risk factors selected from A), B), C) and D): A) previous or existing ar disease selected from myocardial infarction, ry artery disease, percutaneous coronary intervention, coronary artery by-pass ng, ischemic or hagic stroke, congestive heart failure, and peripheral occlusive arterial disease, B) advanced age >/= 60-70 years, and C) one or more cardiovascular risk factors selected from - advanced type 1 or 2 diabetes mellitus > 10 years duration, - hypertension, - current daily cigarette smoking, - dyslipidemia, - obesity, - age >/= 40 - metabolic syndrome, hyperinsulinemia or insulin resistance, and - hyperuricemia, erectile dysfunction, polycystic ovary syndrome, sleep apnea, or family history of vascular disease or cardiomyopathy in degree relative; D) one or more of the following: - confirmed history of myocardial infarction, - unstable angina with documented multivessel coronary disease or positive stress test, - multivessel Percutaneous Coronary Intervention, - multivessel ry Artery By-pass Grafting (CABG), - history of ischemic or hemorrhagic stroke, - peripheral occlusive arterial disease.

In one embodiment, the present invention provides a method of treating a metabolic disorder and ting, reducing the risk of or delaying the occurrence of a cardiovascular event in a patient sing administering empagliflozin, optionally in combination with one or more other therapeutic substances, to the patient. In one embodiment, the metabolic disorder is type 1 or 2 diabetes mellitus or pre-diabetes. In one embodiment, the cardiovascular event is selected from cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalisation for unstable angina pectoris and heart failure requiring hospitalisation.

In one embodiment, the patient with type type 1 or 2 diabetes mellitus or pre-diabetes has one or more cardiovascular risk factors selected from A), B), C) and D): A) previous or existing vascular disease ed from myocardial infarction, coronary artery disease, percutaneous coronary intervention, coronary artery by-pass ng, ischemic or hemorrhagic stroke, congestive heart failure, and peripheral occlusive al e, B) advanced age >/= 60-70 years, and C) one or more cardiovascular risk factors selected from - advanced type 2 diabetes mellitus > 10 years duration, - ension, - current daily tte smoking, - idemia, - obesity, - age >/= 40, - metabolic syndrome, hyperinsulinemia or insulin resistance, and - ricemia, le dysfunction, polycystic ovary me, sleep apnea, or family y of vascular disease or cardiomyopathy in first-degree relative; D) one or more of the following: - confirmed history of myocardial infarction, - unstable angina with documented multivessel coronary disease or positive stress test, - multivessel Percutaneous Coronary Intervention, - multivessel Coronary Artery By-pass ng (CABG), - history of ischemic or hemorrhagic stroke, - peripheral occlusive arterial disease.

In one embodiment, the present invention provides a method of treatment comprising: a) identifying a patient in need of treatment for type 1 or type 2 diabetes and with or at risk of cardiovascular disease; and b) administering empagliflozin to said patient.

In one embodiment, the present invention provides a method of treatment comprising: a) selecting a t with or at risk of cardiovascular disease from a population of patients in need of treatment for type 1 or type 2 diabetes mellitus; b) selecting a type 1 or type 2 diabetes treatment that includes empagliflozin; and c) administering empagliflozin to the patient selected in step a).

In one embodiment, the present invention provides a method of preventing, reducing the risk of or ng the ence of a cardiovascular event in a patient diagnosed with type 1 or type 2 diabetes comprising: a. determining the cardiovascular health of the patient; b. identifying that the patient has or is at risk of a vascular disease; c. administering empagliflozin to the patient.

In one aspect, empagliflozin is stered to the patient if the patient has an elevated risk of a cardiovascular event.

In one embodiment, the patient has or is at risk of a cardiovascular disease selected from myocardial infarction, stroke, peripheral arterial occlusive disease.

In one embodiment, the present invention provides a method for treating a metabolic er in a patient comprising administering a pharmaceutical composition sing empagliflozin to said patient, wherein the risk or occurrence of a cardiovascular event in said patient is reduced. In one embodiment, the cardiovascular event is selected from cardiovascular death, non-fatal dial infarction, non-fatal stroke, hospitalisation for unstable angina pectoris and heart e requiring hospitalisation. In one embodiment, the risk or occurrence of a cardiovascular event is d when compared to a patient administered with a placebo on standard of care background medication. In one embodiment, the risk or occurrence of a cardiovascular event is reduced by 15% or more. In one embodiment, the risk or occurrence of a vascular event is reduced by 16% or more, by 17% or more, by 18% or more, by 19% or more, by 20% or more, by 25% or more or by 30% or more. In one embodiment, ceutical composition comprises 10 mg or 25 mg of iflozin. In one ment, the metabolic disorder is type 1 or type 2 diabetes mellitus or pre-diabetes.

In one embodiment, the patient is a patient with type 1 or type 2 diabetes or pre-diabetes with one or more cardiovascular risk factors selected from A), B), C) and D): W0 2014/161918 _ g _ A) us or existing vascular disease selected from myocardial infarction, coronary artery disease, percutaneous ry intervention, coronary artery by-pass grafting, ischemic or hemorrhagic stroke, congestive heart failure, and peripheral occlusive arterial disease, B) advanced age >/= 60-70 years, and C) one or more cardiovascular risk factors selected from - ed type 1 or type 2 es mellitus > 10 years duration, - hypertension, - current daily cigarette smoking, - dyslipidemia, - y, - age >/= 40, - metabolic syndrome, hyperinsulinemia or insulin resistance, and - hyperuricemia, erectile dysfunction, polycystic ovary syndrome, sleep apnea, or family history of vascular disease or cardiomyopathy in first-degree relative; D) one or more of the following: - confirmed history of myocardial infarction, - unstable angina with nted multivessel coronary disease or positive stress test, - multivessel Percutaneous Coronary Intervention, - multivessel Coronary Artery s ng (CABG), - history of ischemic or hemorrhagic stroke, - peripheral occlusive arterial e.

In one embodiment, the hazard ratio at a one-sided oc—level of 0.025 is < 1.3.

In one embodiment, the present invention provides a method for reducing arterial stiffness in a patient comprising administering empagliflozin to the patient. In one aspect, the patient is a t according to the present invention, in particular a patient with type 1 or type 2 diabetes or pre-diabetes.

In one aspect of the present invention, the one or more other therapeutic substances are selected from other antidiabetic substances, active nces that lower the blood sugar level, active substances that lower the total cholesterol, LDL-cholesterol, Non-HDL- cholesterol and/or Lp(a) level in the blood, active substances that raise the olesterol level in the blood, active nces that lower blood pressure, active substances that are indicated in the treatment of atherosclerosis or obesity, antiplatelet agents, anticoagulant agents, and vascular endothelial protective agents. In one embodiment, the other _ 10 _ antidiabetic nces are selected from metformin, sulphonylureas, nateglinide, repaglinide, PPAR-gamma agonists, glucosidase inhibitors, insulin and insulin analogues, GLP-1 and GLP-1 ues and DPP-4 inhibitors. In one embodiment, the active substances that lower blood pressure are selected from angiotensin receptor blockers (ARB), angiotensin-converting enzyme (ACE) inhibitors, beta-blockers and diuretics. In one aspect, the present invention ses administering empagliflozin in combination with one or more other abetic substances ed from metformin, a sulphonylurea, nateglinide, repaglinide, a DPP-4 inhibitor, a PPAR-gamma agonist, an alpha-glucosidase inhibitor, insulin or insulin analogue, and GLP-1 or GLP-1 analogue. In one , the present invention comprises administering empagliflozin in combination with metformin. In one aspect, the present invention comprises administering empagliflozin in combination with iptin. In one , the present invention comprises stering empagliflozin in ation with metformin and linagliptin. In one aspect, empagliflozin is administered orally in a total daily amount of 10 mg or 25 mg.

In one embodiment, the present invention provides a method of treatment comprising: a) identifying a patient with type 1 or type 2 diabetes treated with a medication to treat a cardiovascular disease; b) administering empagliflozin to said patient; and c) ng the dosage or regimen of said medication to treat a cardiovascular disease in said patient, while continuing to administer empagliflozin to said patient.

In one embodiment, the method further ses monitoring the cardiac health of said patient.

In one embodiment, the present invention provides a method of treatment comprising: a. fying a patient with type 1 or type 2 diabetes treated with a plurality of medications to treat a cardiovascular disease; b. administering empagliflozin to said patient; and c. reducing the number of tions to treat a cardiovascular disease in said patient, while continuing to administer empagliflozin to said patient.

In one embodiment, the method further comprises monitoring the cardiac health of said patient.

In one embodiment, the present invention provides a method of treatment comprising: _ 11 _ a) determining the number, dosage and/or regimen of medications to treat a cardiovascular disease in a patient diagnosed with type 1 or type 2 diabetes; b) ing iflozin as a treatment for type 2 diabetes for the patient; and c) administering empagliflozin to the patient while reducing the number and/or dosage of medications to treat a cardiovascular disease.

In one embodiment, the present invention provides a method of treatment comprising: a) administering empagliflozin to a t diagnosed with type type 1 or 2 diabetes; b) monitoring the cardiac health of said patient; c) adjusting the number, dosage and/or regimen of medications to treat a cardiovascular disease in said patient, while continuing to administer empagliflozin to the patient.

In one embodiment, the present invention provides a method of reducing the risk of a fatal or nonfatal vascular event in a type 1 or type 2 es t comprising administering empagliflozin, optionally in combination with one or more other therapeutic substances, to the patient.

In one embodiment, the fatal or nonfatal cardiovascular event is stroke, myocardial infarction or heart failure. In one embodiment, the patient is at elevated risk of a cardiovascular event.

In one embodiment the patient at elevated risk of a vascular event has a history of coronary artery disease, peripheral arterial e, stroke, transient ischemic attack or high- risk diabetes (insulin-dependent or non-insulin dependent) with evidence of end-organ damage. In one embodiment, the at least one of said one or more other eutic substances is a medication to treat a cardiovascular disease. In one embodiment, the one or more other therapeutic substances is a medication that lower blood pressure are selected from angiotensin receptor blockers (ARB), angiotensin-converting enzyme (ACE) inhibitors, and beta-blockers. In one embodiment, the one or more other eutic substances is a diuretic. In one embodiment, the number, dosage and/or regimen of said medications to treat a cardiovascular disease is reduced is said patient, while the stration of empagliflozin is continued.

In one embodiment, the present invention provides a method of reducing the risk of myocardial infarction, stroke or death from cardiovascular causes or heart e, in particular heart failure requiring hospitalization, in a type 1 or type 2 es patient comprising administering empagliflozin, ally in combination with one or more other _ 12 _ therapeutic substances, to the patient. In one embodiment, the patient is at elevated risk of a cardiovascular event. In one embodiment, the patient at elevated risk of a vascular event has a y of coronary artery disease, peripheral al disease, stroke, transient ischemic attack or high-risk diabetes (insulin-dependent or non-insulin dependent) with evidence of end-organ damage. In one ment, at least one of said one or more other eutic substances is a medication to treat a cardiovascular disease. In one embodiment, the one or more other therapeutic substances is a medication that lower blood pressure are selected from angiotensin receptor blockers (ARB), angiotensin-converting enzyme (ACE) inhibitors, and beta-blockers. In one ment, the one or more other therapeutic substances is a diuretic. In one ment, the number, dosage and/or regimen of said medications to treat a cardiovascular e is reduced is said patient, while the administration of empagliflozin is continued.

In a further embodiment, the present invention provides a method for preventing, slowing, delaying or treating the degeneration of pancreatic beta cells and/or the decline of the functionality of pancreatic beta cells and/or for improving and/or restoring the functionality of pancreatic beta cells and/or restoring the functionality of pancreatic insulin secretion in a patient having latent mune diabetes in adults (LADA), the method comprising administering empagliflozin, optionally in combination with one or more other therapeutic substances, to the patient. In one embodiment, the patient having LADA is a patient in whom one or more autoantibodies selected from GAD (GAD-65, anti-GAD), ICA, lA-2A, ZnT8 (anti- ZnT8) and IAA are t.

In a further embodiment, the present invention provides a method for preserving pancreatic beta cells and/or their on in a patient having latent autoimmune diabetes in adults (LADA), the method comprising administering empagliflozin, optionally in combination with one or more other therapeutic substances, to the t. In one embodiment, the patient having LADA is a patient in whom one or more tibodies selected from GAD (GAD-65, AD), ICA, lA-2A, ZnT8 (anti-ZnT8) and lAA are present.

In a further embodiment, the present invention provides a method for stimulating and/or protecting the functionality of pancreatic insulin secretion in a patient having latent autoimmune diabetes in adults (LADA), the method comprising administering empagliflozin, optionally in combination with one or more other therapeutic nces, to the patient. In one embodiment, the patient having LADA is a patient in whom one or more autoantibodies selected from GAD (GAD-65, anti-GAD), ICA, lA-2A, ZnT8 (anti-ZnT8) and IAA are present.

WO 61918 In a further embodiment, the present invention provides a method for treating and/or preventing LADA (latent autoimmune diabetes of adults), particularly in a patient having LADA in whom one or more autoantibodies ed from GAD (GAD-65, anti-GAD), ICA, IA- 2A, ZnT8 (anti-ZnT8) and IAA are present, the method comprising administering empagliflozin, ally in combination with one or more other therapeutic nces, to the patient.

In one aspect of the present invention, empagliflozin is administered orally, for example in a total daily amount of 10 mg or 25 mg. In one embodiment, empagliflozin is administered as a pharmaceutical composition sing 10 mg or 25 mg of empagliflozin, for example as a In one aspect of the present invention, in a method or use disclosed herein a patient is patient with type 2 diabetes (or type 2 diabetes t), a patient treated for type 2 diabetes, a patient diagnosed with type 2 diabetes or a patient in need of treatment for type 2 diabetes.

In one aspect, a patient is a patient with pre-diabetes.

The present invention further es for empagliflozin or a pharmaceutical composition sing empagliflozin for use as a medicament in any one of the methods described herein.

The present invention further provides for empagliflozin or a pharmaceutical composition comprising empagliflozin for use in the treatment of any one of the es or conditions described herein.

The present invention further provides for empagliflozin or a pharmaceutical composition comprising empagliflozin for use in the cture of a medicament for use in any one of the methods described .

Definitions The term "active ingredient" of a pharmaceutical composition according to the present invention means the SGLT2 inhibitor according to the present invention. An "active ingredient is also sometimes referred to herein as an "active substance". _ 14 _ The term "body mass index" or "BMI" of a human patient is defined as the weight in kilograms divided by the square of the height in meters, such that BMI has units of kg/mz.

The term "overweight" is defined as the ion wherein the individual has a BMI greater than or 25 kg/m2 and less than 30 kg/mz. The terms "ovenNeight" and "pre-obese" are used interchangeably.

The terms "obesity" or "being obese" and the like are defined as the ion n the individual has a BMI equal to or greater than 30 kg/m2. According to a WHO definition the term obesity may be categorized as follows: the term "class I obesity" is the condition wherein the BMI is equal to or greater than 30 kg/m2 but lower than 35 kg/m2; the term "class II obesity" is the condition wherein the BMI is equal to or greater than 35 kg/m2 but lower than 40 kg/m2; the term "class III obesity" is the condition wherein the BMI is equal to or greater than 40 kg/m2.

The indication obesity includes in ular exogenic obesity, nsulinaemic obesity, hyperplasmic obesity, hyperphyseal adiposity, hypoplasmic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, infantile y, upper body obesity, alimentary obesity, hypogonadal obesity, central y, visceral obesity, abdominal obesity.

The term ral obesity" is defined as the condition wherein a waist-to-hip ratio of greater than or equal to 1.0 in men and 0.8 in women is measured. It defines the risk for insulin resistance and the development of pre-diabetes.

The term "abdominal obesity" is y defined as the condition wherein the waist ference is > 40 inches or 102 cm in men, and is > 35 inches or 94 cm in women. With regard to a Japanese ethnicity or se patients abdominal obesity may be defined as waist circumference 2 85 cm in men and 2 90 cm in women (see e.g. investigating committee for the diagnosis of metabolic syndrome in Japan).

The term "euglycemia" is defined as the condition in which a subject has a fasting blood glucose concentration within the normal range, greater than 70 mg/dL (3.89 mmol/L) and less than 100 mg/dL (5.6 mmol/L). The word "fasting" has the usual meaning as a medical term.

The term "hyperglycemia" is d as the condition in which a subject has a fasting blood glucose concentration above the normal range, greater than 100 mg/dL (5.6 mmol/L). The word "fasting" has the usual meaning as a medical term.

The term "hypoglycemia" is defined as the condition in which a subject has a blood glucose tration below the normal range, in particular below 70 mg/dL (3.89 The term "postprandial hyperglycemia" is defined as the condition in which a t has a 2 hour postprandial blood e or serum e concentration greater than 200 mg/dL (11.11 mmol/L).

The term "impaired fasting blood glucose" or "IFG" is defined as the condition in which a subject has a fasting blood glucose concentration or fasting serum glucose concentration in a range from 100 to 125 mg/dl (i.e. from 5.6 to 6.9 mmol/l), in particular greater than 110 mg/dL and less than 126 mg/dl (7.00 mmol/L). A subject with "normal fasting glucose" has a fasting glucose concentration smallerthan 100 mg/dl, i.e. smaller than 5.6 mmol/l.

The term "impaired glucose tolerance" or "IGT" is defined as the condition in which a subject has a 2 hour postprandial blood glucose or serum glucose concentration greater than 140 mg/dl (7.78 mmol/L) and less than 200 mg/dL (11.11 mmol/L). The abnormal glucose tolerance, i.e. the 2 hour postprandial blood glucose or serum e concentration can be measured as the blood sugar level in mg of glucose per dL of plasma 2 hours after taking 75 g of glucose after a fast. A subject with "normal glucose tolerance" has a 2 hour postprandial blood glucose or serum glucose concentration smaller than 140 mg/dl (7.78 mmol/L).

The term "hyperinsulinemia" is d as the condition in which a subject with n resistance, with or without euglycemia, has fasting or postprandial serum or plasma insulin concentration elevated above that of , lean individuals t insulin resistance, having a waist-to-hip ratio < 1.0 (for men) or < 0.8 (for women).

The terms "insulin-sensitizing", "insulin resistance-improving" or "insulin resistance-lowering" are synonymous and used interchangeably.

The term "insulin resistance" is defined as a state in which circulating insulin levels in excess of the normal se to a glucose load are required to maintain the euglycemic state (Ford ES, etal. JAMA. (2002) 287:356-9). A method of determining insulin resistance is the euglycaemic-hyperinsulinaemic clamp test. The ratio of insulin to glucose is determined within the scope of a combined insulin-glucose infusion technique. There is found to be n resistance if the glucose tion is below the 25th tile of the background population igated (WHO definition). Rather less laborious than the clamp test are so called minimal models in which, during an intravenous glucose tolerance test, the insulin and glucose concentrations in the blood are measured at fixed time intervals and from these the insulin resistance is calculated. With this method, it is not possible to distinguish between hepatic and peripheral insulin resistance.

Furthermore, insulin resistance, the response of a patient with insulin resistance to therapy, insulin sensitivity and hyperinsulinemia may be quantified by assessing the "homeostasis model ment to insulin resistance (HOMA-IR)" score, a reliable indicator of insulin resistance (Katsuki A, et al. es Care 2001; 24: 362-5). Further reference is made to methods for the determination of the HOMA—index for insulin sensitivity (Matthews et al., Diabeto/ogia 1985, 28: 412-19), of the ratio of intact proinsulin to insulin (Forsteta/., Diabetes 2003, 52(Suppl. 1): A459) and to an euglycemic clamp study. In addition, plasma adiponectin levels can be monitored as a potential surrogate of insulin sensitivity. The estimate of insulin resistance by the homeostasis assessment model (HOMA)—|R score is calculated with the formula (Galvin P, etal. Diabet Med 1992;9:921-8): HOMA-IR = [fasting serum insulin (uU/mL)] x [fasting plasma glucose(mmol/L)/22.5] Insulin resistance can be confirmed in these individuals by calculating the HOMA-IR score.

For the e of this invention, insulin resistance is d as the clinical condition in which an individual has a HOMA-IR score > 4.0 or a R score above the upper limit of normal as defined for the laboratory performing the e and insulin .

As a rule, other parameters are used in everyday clinical practice to assess insulin resistance. Preferably, the patient's ceride concentration is used, for example, as increased triglyceride levels ate significantly with the presence of insulin resistance.

Individuals likely to have n resistance are those who have two or more of the following attributes: 1) ovenNeight or obese, 2) high blood pressure, 3) hyperlipidemia, 4) one or more 1St degree relative with a sis of IGT or IFG or type 2 diabetes.

W0 2014/161918 _ 17 _ Patients with a predisposition for the development of lGT or IFG or type 2 es are those having euglycemia with hyperinsulinemia and are by definition, insulin ant. A typical patient with insulin resistance is usually overweight or obese. lf insulin resistance can be detected, this is a ularly strong indication of the presence of pre-diabetes. Thus, it may be that in order to maintain glucose homoeostasis a person needs 2-3 times as much insulin as a healthy person, without this resulting in any clinical symptoms.

"Pre-diabetes" is a general term that refers to an intermediate stage between normal glucose tolerance (NGT) and overt type 2 diabetes mellitus (T2DM), also referred to as intermediate hyperglycaemia. As such, it represents 3 groups of individuals, those with impaired glucose tolerance (IGT) alone, those with impaired fasting e (IFG) alone or those with both IGT and IFG. IGT and IFG usually have distinct pathophysiologic etiologies, r also a mixed condition with es of both can exist in patients. Therefore in the context of the t invention a patient being diagnosed of having "pre-diabetes" is an dual with diagnosed lGT or diagnosed IFG or diagnosed with both IGT and IFG.

Following the definition according to the American Diabetes ation (ADA) and in the context of the present invention a patient being diagnosed of having "pre-diabetes" is an individual with: a) a fasting plasma glucose (FPG) concentration <100 mg/dL [1 mg/dL = 0.05555 mmol/L] and a 2-hour plasma glucose (PG) concentration, measured by a 75-9 oral glucose tolerance test , ranging between 2140 mg/dL and <200 mg/dL (i.e., IGT); or b) a fasting plasma glucose (FPG) concentration n 2100 mg/dL and <126 mg/dL and a 2-hour plasma e (PG) concentration, measured by a 75-9 oral glucose tolerance test (OGTT) of <140 mg/dL (i.e., IFG); or c) a fasting plasma glucose (FPG) concentration between 2100 mg/dL and <126 mg/dL and a 2-hour plasma glucose (PG) tration, measured by a 75-9 oral glucose tolerance test (OGTT), ranging between 2140 mg/dL and <200 mg/dL (i.e., both IGT and IFG).

Patients with "pre-diabetes" are individuals being pre-disposed to the development of type 2 diabetes. abetes extends the definition of lGT to include individuals with a fasting blood glucose within the high normal range 2 100 mg/dL (J. B. Meigs, et al. Diabetes 2003; 52:1475-1484). The scientific and medical basis for identifying pre-diabetes as a serious health threat is laid out in a Position Statement entitled "The tion or Delay of Type 2 Diabetes" issued jointly by the American Diabetes Association and the National Institute of Diabetes and Digestive and Kidney Diseases (Diabetes Care 2002; 25:742-749). 2014/056655 The methods to investigate the function of pancreatic beta-cells are similar to the above s with regard to n sensitivity, hyperinsulinemia or insulin resistance: An improvement of beta-cell function can be ed for example by ining a HOMA- index (homeostasis model assessment) for beta-cell function, HOMA—B, (Matthews et al., Diabetologia 1985, 28: 412-19), the ratio of intact proinsulin to insulin (Forst et al., Diabetes 2003, 52(Suppl. 1): A459), first and second phase n secretion after an oral glucose tolerance test or a meal tolerance test (Stumvoll et al., Diabetes care 2000, 23: 295-301), the insulin/C-peptide secretion after an oral glucose tolerance test or a meal tolerance test, or by employing a hyperglycemic clamp study and/or minimal modeling after a frequently sampled intravenous glucose tolerance test (Stumvoll et al., EurJ Clin Invest 2001, 31: 380-81).

The term "type 1 diabetes" is defined as the condition in which a subject has, in the presence of autoimmunity s the pancreatic beta-cell or insulin, a fasting blood glucose or serum glucose concentration greater than 125 mg/dL (6.94 mmol/L). If a glucose tolerance test is carried out, the blood sugar level of a diabetic will be in excess of 200 mg of glucose per dL (11.1 mmol/l) of plasma 2 hours after 75 g of glucose have been taken on an empty stomach, in the presence of autoimmunity towards the pancreatic beta cell or insulin. In a glucose tolerance test 75 g of glucose are administered orally to the patient being tested after 10-12 hours of fasting and the blood sugar level is ed immediately before taking the glucose and 1 and 2 hours after taking it. The presence of munity towards the pancreatic beta-cell may be observed by detection of circulating islet cell autoantibodies ["type 1A diabetes mellitus"], i.e., at least one of: GAD65 [glutamic acid decarboxylase-65], ICA -cell cytoplasm], lA—2 [intracytoplasmatic domain of the tyrosine phosphatase-like protein lA—2], ZnT8 [zinc-transporter-8] or anti-insulin; or other signs of autoimmunity without the presence of typical circulating autoantibodies [type 18 diabetes], i.e. as detected h pancreatic biopsy or imaging). Typically a genetic predisposition is present (e.g. HLA, INS VNTR and PTPN22), but this is not always the case.

The term "type 2 diabetes us" or "T2DM" is defined as the condition in which a subject has a fasting blood e or serum glucose tration greater than 125 mg/dL (6.94 mmol/L). The measurement of blood glucose values is a standard procedure in routine l analysis. If a glucose tolerance test is carried out, the blood sugar level of a diabetic will be in excess of 200 mg of e per dL (11.1 mmol/l) of plasma 2 hours after 75 g of glucose have been taken on an empty stomach. In a glucose tolerance test 75 g of glucose are administered orally to the patient being tested after 10-12 hours of fasting and the blood sugar level is recorded immediately before taking the glucose and 1 and 2 hours after taking _ 1g _ it. In a healthy subject, the blood sugar level before taking the glucose will be between 60 and 110 mg per dL of plasma, less than 200 mg per dL 1 hour after taking the e and less than 140 mg per dL after 2 hours. If after 2 hours the value is between 140 and 200 mg, this is regarded as abnormal glucose tolerance.

The term "late stage type 2 es us" includes patients with a secondary drug failure, indication for insulin therapy and ssion to micro- and macrovascular complications e.g. diabetic nephropathy, or coronary heart disease (CH D).

The term "LADA" ("latent autoimmune diabetes of adults") refers to patients that have a clinical diagnosis of type 2 diabetes, but who are being detected to have autoimmunity towards the pancreatic beta cell. Latent autoimmune diabetes of adults (LADA) is also known as slowly progressive type 1 diabetes mellitus , "mild" T1 DM, non-insulin dependent type 1 DM, type 1 1/2 DM, double es or antibody positive type 2 DM . LADA is often not clearly defined and, opposed to T1 DM, seldom or never presents with significant weight loss and ketoacidosis due to rapidly progressive B-cell failure.

The term "HbA1c" refers to the product of a non-enzymatic glycation of the haemoglobin B chain. lts determination is well known to one skilled in the art. In monitoring the treatment of diabetes mellitus the HbA1c value is of exceptional ance. As its production depends essentially on the blood sugar level and the life of the ocytes, the HbA1c in the sense of a "blood sugar " reflects the average blood sugar levels of the preceding 4-6 weeks. Diabetic patients whose HbA1c value is consistently well adjusted by intensive diabetes treatment (i.e. < 6.5 % of the total haemoglobin in the sample), are significantly better protected t diabetic microangiopathy. For example, metformin on its own achieves an average improvement in the HbA1c value in the diabetic of the order of 1.0 — 1.5 %. This ion of the HbA1C value is not sufficient in all diabetics to achieve the desired target range of <7% or < 6.5 % and preferably < 6 % HbA1c.

The term ficient glycemic control" or "inadequate glycemic control" in the scope of the present invention means a condition wherein patients show HbA1c values above 6.5 %, in particular above 7.0 %, even more preferably above 7.5 %, especially above 8 %.

The "metabolic syndrome", also called "syndrome X" (when used in the context of a metabolic disorder), also called the "dysmetabolic syndrome" is a syndrome complex with the cardinal feature being insulin resistance (Laaksonen DE, et al. Am J Epidemiol 2002;156:1070-7). According to the ATP Ill/NCEP guidelines (Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel lll) JAMA: Journal of the American Medical ation (2001) 285:2486-2497), diagnosis of the metabolic syndrome is made when three or more of the following risk factors are present: 1. Abdominal obesity, defined as waist circumference > 40 inches or 102 cm in men, and > 35 inches or 94 cm in women; or with regard to a Japanese ethnicity or Japanese ts defined as waist circumference 2 85 cm in men and 2 90 cm in women; 2. Triglycerides: 2 150 mg/dL 3 HDL-cholesterol < 40 mg/dL in men 4. Blood pressure 5 mm Hg (SBP 2130 or DBP 2 85) Fasting blood e 2 100 mg/dL The NCEP definitions have been validated (Laaksonen DE, et al. Am J Epidemiol. (2002) 156:1070-7). Triglycerides and HDL terol in the blood can also be determined by standard methods in medical analysis and are described for example in Thomas L (Editor): "Labor und Diagnose", TH-Books Verlagsgesellschaft mbH, Frankfurt/Main, 2000.

According to a commonly used definition, hypertension is sed if the systolic blood pressure (SBP) exceeds a value of 140 mm Hg and lic blood pressure (DBP) exceeds a value of 90 mm Hg. If a patient is suffering from manifest diabetes it is currently recommended that the systolic blood pressure be d to a level below 130 mm Hg and the diastolic blood re be lowered to below 80 mm Hg.

The term "empagliflozin" refers to the SGLT2 inhibitor 1-chloro(B-D-glucopyranosy|)- 2-[4-((S)—tetrahydrofuranyloxy)—benzyl]—benzene of the formula as described for example in . Methods of synthesis are described in the literature, for example WO 208 and . According to this invention, it is to be understood that the definition of empagliflozin also comprises its hydrates, solvates and polymorphic forms thereof. An advantageous crystalline form of empagliflozin is described in WO 17359 and which hereby are incorporated herein in their entirety. This crystalline form possesses good solubility ties which enables a good bioavailability of the SGLT2 inhibitor. Furthermore, the crystalline form is physico- chemically stable and thus provides a good shelf-life stability of the pharmaceutical composition. Preferred pharmaceutical compositions, such as solid formulations for oral administration, for example tablets, are described in , which hereby is incorporated herein in its entirety.

The terms ment" and "treating" comprise therapeutic treatment of patients having already developed said condition, in particular in manifest form. eutic treatment may be symptomatic ent in order to relieve the symptoms of the specific indication or causal treatment in order to reverse or partially reverse the conditions of the indication or to stop or slow down progression of the disease. Thus the compositions and methods of the present invention may be used for instance as therapeutic treatment over a period of time as well as for chronic therapy.

The terms "prophylactically treating", ntivally treating" and "preventing" are used interchangeably and comprise a ent of patients at risk to develop a condition mentioned before, thus reducing said risk.

The term "tablet" comprises tablets without a coating and tablets with one or more coatings. Furthermore the "term" tablet comprises s having one, two, three or even more layers and press-coated tablets, wherein each of the mentioned types of tablets may be without or with one or more coatings. The term "tablet" also ses mini, melt, chewable, effervescent and orally egrating tablets.

The terms "pharmacopoe" and "pharmacopoeias" refer to standard pharmacopoeias such as the "USP 31–NF 26 through Second Supplement" (United States Pharmacopeial Convention) or the "European Pharmacopoeia 6.3" (European Directorate for the Quality of Medicines and Health Care, 2000-2009).

Brief Description of the Drawings Figure 1: weight gain, blood glucose (non-fasting and fasting, n=6-8) and HbA1c (n=5-6) in animals treated with iflozin. (22430938_1):KZA _ 22 _ Figure 2A and 2B: relaxation (endothelial function) deteriorated in STZ treated (diabetic) animal and after ent with empagliflozin. The GTN curve on figure 2B is the ve control to show that in Nitric oxide supplies, all tissues equivalent showing the ity of the vessels wall.

Figure 3: oxidative burst (leukocyte-derived reactive oxygen species (ROS)) in blood upon ZymA stimulation at 30 minutes.

Figure 4: oxidative burst (leukocyte-derived ROS) in blood upon ZymA stimulation at 60 minutes.

Figure 5: time course of oxidative burst (leukocyte-derived ROS) in blood upon ZymA stimulation.

Figure 6: oxidative burst (leukocyte-derived ROS) in blood upon ZymA stimulation (at 30 s) with inhibitors of Nox2 activity (VAS2870) and an intracellular calcium chelator.

Figure 7: oxidative burst (leukocyte-derived ROS) in blood upon ZymA ation (at 60 minutes) with inhibitors of Nox2 activity 70) and an intracellular calcium chelator..

Figure 8: oxidative burst (leukocyte-derived ROS) in blood upon PDBu stimulation at 15 minutes.

Figure 9: time course of oxidative burst cyte-derived ROS) in blood upon PDBu stimulation.

Figure 10: membraneous NADPH oxidase activity.

Figure 11A and 11B: liver ALDH-2 activity.

Figure 12A and 12B: vascular superoxide formation by fluorescent DHE microtopography.

Figure 13 A-D: serum levels of cholesterol, triglyceride, n and interferon-gamma, respectively.

Figure 14: Hourly mean Systolic Blood Pressure (SBP) at Week 12 .

Figure 15: Hourly mean Systolic Blood Pressure (SBP) at Week 12 (mmHg).

Figure 16A and 16B: microscopic determination of aortic wall thickness and collagen content by sirius red staining of aortic paraffinated sections.

Detailed Description of the Invention The t invention relates to certain SGLT-2 inhibitors, in particular empagliflozin, for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes. The present invention further relates to certain SGLT-2 inhibitors, in particular empagliflozin, for treating and/or preventing endothelial dysfunction. The present invention further s to certain SGLT-2 inhibitors, in particular empagliflozin, to reduce glucotoxicity and associated oxidative stress and inflammation in the tissues.The present invention also _ 23 _ relates to the use of such SGLT-2 inhibitors in the treatment and/or prevention of cardiovascular diseases in patients, for example in type 1 or type 2 diabetes patients. The present invention also relates to the use of such SGLT-2 tors, in particular empagliflozin, in treatment and/or prevention of metabolic disorders in patients with or at risk of cardiovascular disease. The present ion further relates to certain SGLT-2 inhibitors, in particular empagliflozin, for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for e patients with type 1 or type 2 diabetes.

The present invention further relates to certain SGLT-2 inhibitors, in particular empagliflozin, for treating and/or preventing ive stress, vascular stress and/or endothelial dysfunction (e.g. in diabetes or non-diabetes patients), particularly independently from or beyond glycemic control.

The present invention further relates to certain SGLT-2 inhibitors, in particular empagliflozin, for treating and/or preventing collagen deposition and/or vessel wall thickening (e.g. in es or non-diabetes patients), particularly independently from or beyond ic control.

The present invention further relates to certain SGLT-2 inhibitors, in particular empagliflozin, for treating and/or preventing hyperglycemia-induced or -associated oxidative stress (e.g. beyond glycemic control), as well as to the use of such SGLT-2 inhibitors in antidiabetic The t ion further relates to certain SGLT-2 inhibitors, in particular iflozin, for treating and/or preventing metabolic disorders, such as es, especially type 1 and type 2 diabetes mellitus and/or es related thereto (e.g. diabetic complications), particularly in patients having or being at risk of oxidative stress, vascular stress and/or endothelial dysfunction, or diseases or conditions related or associated therewith.

Further, the t invention relates to certain SGLT-2 inhibitors, in particular empagliflozin, for treating and/or preventing metabolic disorders, such as diabetes, especially type 1 and type 2 diabetes us and/or diseases related thereto (e.g. diabetic complications), in patients having or being at risk of vascular e, such as eg. myocardial infarction, stroke or peripheral arterial occlusive disease, or micro- or macroalbuminuria. _ 24 _ Further, the present ion relates to certain SGLT-2 inhibitors, in particular iflozin, for treating and/or preventing lic ers, such as diabetes, especially type 1 and type 2 diabetes mellitus and/or es related thereto, in patients having or being at risk of micro- or macrovascular ic complications, such as e.g. diabetic retinopathy, ic neuropathy, diabetic nephropathy, or cardiovascular diseases (such as e.g. myocardial infarction, stroke or peripheral arterial occlusive diasease).

Further, the present invention relates to certain SGLT-2 tors, in particular empagliflozin, for modulating, blocking or reducing deleterious metabolic memory effect of (chronic or transient es of) hyperglycemia, ularly on diabetic complications.

Further, the present ion relates to certain SGLT-2 inhibitors, in particular empagliflozin, for treating, ting or ng risk for micro- or macrovascular diseases which may be induced, memorized by or associated with exposure to oxidative stress.

Furthermore, the t invention s to a certain SGLT-2 inhibitor, in particular empagliflozin, for treating and/or preventing metabolic disorders, such as diabetes, ally type 1 and type 2 diabetes mellitus and/or diseases related thereto (e.g. diabetic complications), in patients with or at risk of cardiovascular disease, particularly in those type 1 or type 2 diabetes patients being at risk of cardiovascular events, such as type 1 or type 2 diabetes patients with one or more risk factors selected from previous or existing vascular disease (such as e.g. myocardial infarction (e.g. silent or non-silent), coronary artery disease, percutaneous coronary intervention, coronary artery by-pass grafting, ischemic or hemorrhagic stroke, congestive heart failure (e.g. NYHA class I or II, e.g. left ventricular function <40%), or peripheral occlusive arterial disease), said method comprising stering a therapeutically effective amount of the SGLT-2 inhibitor, optionally in combination with one or more other therapeutic substances, to the patient.

Oxidative stress represents an imbalance between the production of reactive oxygen species (which include free radicals, which typically have an - or nitrogen based unpaired electron in their outer orbitals and peroxides) and a biological system's ability to readily detoxify the reactive intermediates or to repair the resulting damage. Disturbances in the normal redox state of tissues can cause toxic effects through the production of peroxides and free radicals that damage all components of the cell, including proteins, lipides and nucleic acid/DNA. Oxidative stress can target many organs (such as blood vessels, eyes, heart, skin, kidney, joints, lung, brain, immune system, liver, or multi-organs) and can be involved in many diseases and conditions. Examples of such diseases or conditions associated with oxidative stress include atherosclerosis (e.g. platelet activation and atheromatous plaque formation), endothelial dysfunction, restenosis, ension, peripheral occlusive vascular e, ia-reperfusion injuries (e.g. renal, c, cardiac or cerebral ischemia- reperfusion injuries), fibrosis (e.g. renal, hepatic, cardiac or pulmonary fibrosis); macular degeneration, retinal degeneration, cateracts, retinopathy; coronary heart disease, ischemia, dial infarction; psoriasis, dermatitis; chronic kidney disease, nephritis, acute renal failure, glomerulonephritis, nephropathy; rheumatoid arthritis, osteoarthritis; asthma, COPD, respiratory distress syndrome; stroke, neurodegenerative diseases (e.g. Alzheimer’s disease, Parkinson’s e, Huntington’s disease), schizophrenia, bipolar disorder, obsessive compulsive disorder; chronic systemic mations, perivascular inflammation, autoimmune disorders, multiple sclerosis, lupus erythematosus, inflammatory bowel disease, tive colitis; NAFLD/NASH; chronic fatigue syndrome, stic ovary syndrome, sepsis, diabetes, metabolic syndrome, insulin resistance, hyperglycemia, hyperinsulinemia, dyslipidemia, holesterolemia, ipidemia, etc. In addition to their al pharmacological properties, certain drugs used clinically, including, without being limited, anti-hypertension agents, angiotensin or blockers and antihyperlipidemic agents such as statins, protect various organs via anti-oxidative stress mechanisms. ts with or at risk of oxidative and/or vascular stress can be diagnosed by ining t’s oxidative stress markers, such as e.g. oxidized LDL, markers of inflammatory status (e.g. pro-inflammatory interleukins), 8—OHdG, isoprostanes (e.g. F2-isoprostanes, 8—iso- prostaflandin F2alpha), yrosine, or N-carboxymethyl lysine (CML).

Endothelial dysfunction, commonly assessed clinically as impaired endothelium-dependent vasomotion (e.g. imbalance between vasodilating and vasoconstricting), is a physiological lity of endothelial cells, the cells that line the inner surface of blood vessels, arteries and veins, that prevents them from carrying out their normal biochemical functions. Normal endothelial cells are involved in mediating the processes of coagulation, platelet adhesion, immune function, control of volume and electrolyte content of the intravascular and extravascular spaces. Endothelial dysfunction is associated with proinflammatory, pro- oxidative and prothrombotic changes within the arterial wall as well as increase vessel wall thickness and collagen content. Endothelial dysfunction is thought to be a key event in the development and progression of atherosclerosis and arterial stiffness, and predates clinically obvious vascular complications. elial dysfunction is of prognostic significance in _ 26 _ detecting vascular disease and predicting adverse vascular events. Risk factors for atherosclerosis and ar disease/events are associated with endothelial dysfunction.

Endothelial damage also contributes to the development of renal injury and/or chronic or progressive kidney damages, such as e.g. tubulointerstitial fibrosis, glomerulonephritis, micro-or macroalbuminuria, nephropathy and/or chronic kidney disease or renal failure.

There is supporting evidence that oxidative stress does not only contribute to endothelial ction or damage but also to vascular disease.

Type 2 diabetes mellitus is a common c and progressive disease g from a complex pathophysiology involving the dual endocrine effects of insulin resistance and impaired insulin secretion with the uence not meeting the required demands to maintain plasma glucose levels in the normal range. This leads to hyperglycaemia and its associated micro- and macrovascular complications or chronic damages, such as e.g. diabetic nephropathy, retinopathy or neuropathy, or macrovascular (e.g. cardiovascular) complications. The ar disease component plays a significant role, but is not the only factor in the spectrum of diabetes associated disorders. The high frequency of complications leads to a significant reduction of life expectancy. es is currently the most frequent cause of adult-onset loss of vision, renal e, and amputation in the lndustrialised World because of diabetes induced complications and is associated with a two to five fold increase in cardiovascular disease risk. Type 1 diabetes mellitus (Type 1 diabetes), also called insulin dependent diabetes mellitus or juvenile diabetes, is a form of es mellitus that results from mune destruction of insulin-producing beta cells of the pancreas. The subsequent lack of insulin leads to increased blood glucose concentrations and sed urinary glucose excretion. The classical symptoms are polyuria, polydipsia, polyphagia, and weight loss. Type 1 diabetes may be fatal unless treated with insulin. Complications from type 1 diabetes are the same or r to complications from type 2 diabetes.

Large randomized studies have established that intensive and tight ic control during early (newly diagnoses to 5 years) stage diabetes has enduring cial effects and reduces the risk of diabetic complications, both micro- and macrovascular. However, many patients with diabetes still develop ic complications despite receiving intensified glycemic l.

Epidemiological and prospective data t a long-term influence of early (newly diagnosed to 5 years) lic control on clinical outcomes. It has been found that hyperglycemia has long-lasting deleterious effects both in type 1 and type 2 diabetes and W0 2014/161918 _ 27 _ that glycemic control, if not started at a very early stage of the disease or not intensively or not tightly provided, may not be enough to completely reduce complications.

It has been r found that transient episodes of hyperglycemia (e.g. hyperglycemic events), can induce lar changes, and that these changes can persist or are irreversible after return to normoglycemia.

Collectively, these data suggest that metabolic memories are stored early in the course of diabetes and that, in certain ic conditions, oxidative and/orvascular stresses can persist after glucose normalization. This phenomenon that early ic environment, and/or even transient hyperglycemia, is remembered with al uences in the target end organs (e.g. blood vessels, retina, kidney, heart, extremities) has recently been termed as ‘metabolic memory.’ Potential mechanisms for propagating this ‘memory’ are certain epigenetic changes, the non- enzymatic glycation of cellular proteins and lipids (e.g. formation of advanced glycation end- products), oxidatively modified genic oteins, and/or an excess of cellular ve oxygen and nitrogen species (RONS), in particular ated at the level of glycated- mitochondrial proteins, perhaps acting in concert with one another to maintain stress signalling.

Mitochondria are one of major sources of recative oxygen species (ROS) in cells.

Mitochondrial dysfunction increases electron leak and the generation of ROS from the mitochondrial respiratory chain (MRC). High levels of glucose and lipids impair the activities of MRC complex enzymes. For e, the MRC enzyme NADPH oxidase generates superoxide from NADPH in cells. Increased NADPH oxidase activity can be detected in diabetic ts.

Further, there is evidence that oduction of free radicals, such as e.g. reactive oxygen species (ROS), contributes to oxidative and vascular stress after glucose normalization and to developing and/or maintaining the metabolic memory, and thus to the unifying link between hyperglycemia and ar memory effects, such as e.g. in endothelial dysfunction or other complications of diabetes.

Thus, mainly related to persisting (long-term) oxidative stress induced by or associated with (chronic, early or transient episodes of) hyperglycemia, there are certain metabolic ions in that, even normalizing glycemia, a long-term persitent activation of many pathways involved in the pathogenesis of diabetic complications can still be present. One of the major findings in the course of diabetes has thereby been the tration that even in normoglycemia and independent of the actual glycemic levels an overproduction of free _ 28 _ radicals can still be evident. For e, endothelial dysfunction (a causative marker of diabetic vascular complications) can persist even after normalizing glycemia. r, there is evidence that combining antioxidant y with normalization of glycemia can be used to almost upt endothelial dysfunction.

Therefore, treating oxidative and/or vascular stress particularly beyond glycemic control, such as by the ion of cellular reactive species and/or of glycation (e.g. by inhibition of the production of free oxygen and nitrogen ls), preferably independently of glycemic status, may beneficially modulate, , block or protect against the memory’ effect of hyperglycemia and reduce the risk, prevent, treat or delay the onset of long-term diabetic complications, particularly such ones which are associated with or induced by oxidative stress, in ts in need thereof.

Standard therapy of type 1 diabetes is insulin treatment. Therapies for type 1 es are for example bed in .

The treatment of type 2 diabetes typically begins with diet and exercise, followed by oral antidiabetic monotherapy, and although conventional monotherapy may lly control blood glucose in some patients, it is however ated with a high secondary failure rate. The limitations of single-agent therapy for maintaining glycemic control may be overcome, at least in some patients, and for a limited period of time by combining multiple drugs to e reductions in blood glucose that cannot be sustained during long-term therapy with single agents. Available data t the conclusion that in most patients with type 2 diabetes current monotherapy will fail and treatment with multiple drugs will be required.

But, because type 2 diabetes is a progressive disease, even patients with good initial responses to conventional combination therapy will eventually require an increase of the dosage or further treatment with n because the blood glucose level is very difficult to maintain stable for a long period of time. Although existing ation therapy has the potential to enhance glycemic l, it is not without limitations (especially with regard to long term efficacy). Further, traditional therapies may show an increased risk for side effects, such as hypoglycemia or weight gain, which may compromise their efficacy and acceptability.

Thus, for many patients, these existing drug therapies result in progressive deterioriation in metabolic control despite treatment and do not sufficiently control metabolic status ally over long-term and thus fail to achieve and to maintain glycemic control in advanced or late stage type 2 diabetes, including diabetes with inadequate glycemic control despite conventional oral or non-oral antidiabetic medication.

Therefore, although intensive treatment of hyperglycemia can reduce the incidence of chronic damages, many ts with type 2 diabetes remain inadequately treated, partly because of tions in long term efficacy, tolerability and dosing inconvenience of conventional antihyperglycemic therapies.

This high incidence of therapeutic failure is a major contributor to the high rate of long-term hyperglycemia-associated complications or c damages (including micro- and makrovascular complications such as e.g. diabetic nephrophathy, retinopathy or neuropathy, or cardiovascular complications such as e.g. myocardial infarction, stroke or vascular mortality or morbidity) in patients with type 2 diabetes.

Oral antidiabetic drugs conventionally used in therapy (such as e.g. first- or -line, and/or mono- or (initial or add-on) combination therapy) e, without being restricted thereto, metformin, nylureas, thiazolidinediones, DPP-4 tors, glinides and or- glucosidase inhibitors.

Non-oral (typically injected) antidiabetic drugs conventionally used in therapy (such as e.g. first— or second-line, and/or mono- or (initial or add-on) combination therapy) e, t being restricted thereto, GLP-1 or GLP-1 analogues, and insulin or insulin analogues.

However, the use of these conventional antidiabetic or antihyperglycemic agents can be associated with various adverse effects. For example, metformin can be associated with lactic acidosis or gastrointestinal side effects; sulfonylureas, glinides and n or insulin analogues can be associated with hypoglycemia and weight gain; thiazolidinediones can be associated with edema, bone fracture, weight gain and heart e/cardiac effects; and alpha-glucosidase blockers and GLP-1 or GLP-1 analogues can be associated with gastrointestinal adverse effects (e.g. dyspepsia, flatulence or diarrhea, or nausea or vomiting) and, most seriously (but rare), atitis.

Therefore, it remains a need in the art to provide efficacious, safe and tolerable antidiabetic ies.

Further, within the therapy of type 2 diabetes, it is a need for treating the condition effectively, avoiding the complications inherent to the ion, and delaying disease progression, e.g. in order to achieve a long-lasting therapeutic benefit.

Furthermore, it remains a need that antidiabetic treatments not only prevent the long-term Moreover, it remains a need to e prevention or reduction of risk for adverse effects associated with tional abetic therapies.

SGLT2 inhibitors (sodium-glucose co-transporter 2) represent a novel class of agents that are being developed for the treatment or improvement in glycemic control in patients with type 2 diabetes. Glucopyranosyl-substituted benzene derivative are described as SGLT2 inhibitors, for example in WO 01/27128, WO 03/099836, , WO 2006/034489, , , , , , , , , WO 2008/049923, WO 55870, . The glucopyranosyl-substituted benzene derivatives are proposed as inducers of urinary sugar ion and as ments in the treatment of es.

Renal filtration and reuptake of glucose contributes, among other mechanisms, to the steady state plasma glucose concentration and can therefore serve as an antidiabetic target.

Reuptake of filtered glucose across epithelial cells of the kidney proceeds via sodium- dependent glucose cotransporters (SGLTs) located in the brush-border membranes in the tubuli along the sodium gradient. There are at least 3 SGLT isoforms that differ in their expression n as well as in their physico-chemical properties. SGLT2 is exclusively expressed in the kidney, s SGLT1 is expressed additionally in other tissues like intestine, colon, skeletal and cardiac muscle. SGLT3 has been found to be a glucose sensor in interstitial cells of the intestine t any transport function. Potentially, other related, but not yet characterized genes, may contribute further to renal glucose reuptake. Under normoglycemia, glucose is completely reabsorbed by SGLTs in the kidney, whereas the reuptake capacity of the kidney is saturated at glucose concentrations higher than 10mM, resulting in glucosuria ("diabetes mellitus"). This threshold concentration can be decreased by inhibition. It has been shown in experiments with the SGLT inhibitor phlorizin that SGLT-inhibition will partially inhibit the reuptake of glucose from the glomerular filtrate into the blood leading to a decrease in blood e concentration and to glucosuria.

Empagliflozin is a novel SGLT2 inhibitor that is bed for the treatment or improvement in glycemic control in patients with type 2 diabetes mellitus, for example in WC 877, WO 06/117359, WO 06/120208, , , , WO 2011/039108.

Accordingly, in a particular embodiment, a SGLT-2 tor within the meaning of this invention is empagliflozin. r, the present invention relates to a therapeutic (treatment or prevention) method as described herein, said method comprising administering an effective amount of a SGLT-2 inhibitor as described herein and, optionally, one or more other active or therapeutic agents as described herein to the patient in need thereof.

In one ment, diabetes ts within the g of this invention may include patients who have not previously been treated with an antidiabetic drug nai've patients). Thus, in an embodiment, the therapies bed herein may be used in naive patients. In another embodiment, diabetes patients within the meaning of this invention may include patients with advanced or late stage type 2 diabetes mellitus (including patients with failure to conventional antidiabetic therapy), such as e.g. patients with inadequate glycemic control on one, two or more tional oral and/or non-oral antidiabetic drugs as defined herein, such as e.g. patients with icient glycemic control despite (mono-)therapy with metformin, a thiazolidinedione (particularly pioglitazone), a sulphonylurea, a e, a DPP-4 inhibitor, GLP-1 or GLP-1 analogue, insulin or insulin ue, or an d-glucosidase inhibitor, or despite dual ation therapy with metformin/sulphonylurea, metformin/thiazolidinedione cularly pioglitazone), metformin/DPP-4 inhibitor, sulphonylurea/ d-glucosidase inhibitor, pioglitazone/sulphonylurea, metformin/insulin, pioglitazone/insulin or sulphonylurea/insulin. Thus, in an embodiment, the ies described herein may be used in patients experienced with therapy, e.g. with conventional oral and/or non-oral antidiabetic mono- or dual or triple combination medication as mentioned herein.

A further embodiment of diabetic ts within the meaning of this invention refers to type 1 or type 2 diabetes patients with or at risk of developping micro- or macrovascular diabetic complications, such as e.g. described herein (e.g. such at risk patients as described as follows).

A further embodiment of the diabetes patients which may be amenable to the therapies of this invention may include, without being limited, those type 1 or type 2 diabetes patients with or at risk of developping retinal complications, such as diabetic retinopathy. _ 32 _ A further ment of the diabetes patients which may be amenable to the therapies of this invention may e, without being limited, those type 1 or type 2 diabetes patients with or at risk of developping macrovascular complications, such as myocardial infarction, coronary artery disease, ischemic or hemorrhagic stroke, and/or peripheral ive arterial disease.

A further embodiment of the diabetes patients which may be amenable to the therapies of this invention may include, without being limited, those type 1 or type 2 diabetes patients with or at risk of cardiovascular diseases or events (such as eg. those cardiovascular risk patients described herein).

A further embodiment of the diabetes ts which may be amenable to the therapies of this invention may include, without being limited, those diabetes patients (especially type 2 diabetes) with advanced age and/or with ed es disease, such as eg. patients on insulin treatment, ts on triple antidiabetic oral therapy, ts with pre-existing cardiovascular events and/or patients with ed disease duration (e.g. >/= 5 to 10 years).

According to one aspect of the present invention a patient is a type 1 or type 2 diabetes patient.

In one embodiment, the patient is a type 1 or type 2 diabetes patient with one or more cardiovascular risk factors selected from A), B), C) and D): A) previous or existing vascular disease selected from myocardial infarction, coronary artery disease, percutaneous coronary intervention, coronary artery by-pass grafting, ischemic or hemorrhagic stroke, congestive heart failure, and peripheral occlusive arterial disease, B) advanced age >/= 60-70 years, and C) one or more cardiovascular risk factors selected from - advanced type 2 diabetes us > 10 years duration, - hypertension, - current daily cigarette smoking, - dyslipidemia, - y, - age >/= 40, - lic syndrome, hyperinsulinemia or insulin ance, and - hyperuricemia, erectile dysfunction, polycystic ovary syndrome, sleep apnea, or family history of vascular disease or cardiomyopathy in first-degree relative; D) one or more of the following: med history of myocardial infarction, unstable angina with documented multivessel coronary disease or ve stress test, multivessel aneous Coronary ention, multivessel Coronary Artery By-pass Grafting (CABG), history of ischemic or hemorrhagic stroke, eral occlusive arterial disease.

In a further aspect of the present invention, a patient having at risk of a cardiovascular disease is d as having at least one of the following: Confirmed history of myocardial infarction; or Evidence of multivessel coronary artery disease, in 2 or more major coronary arteries, irrespective of the revascularization status, Le. a) Either the ce of a significant is (imaging evidence of at least 50% narrowing of the luminal diameter measured during a coronary angiography or a multi-sliced computed tomography angiography), in 2 or more major coronary arteries, b) Or a previous revascularisation (percutaneous transluminal coronary angioplasty with or without stent, or coronary artery bypass grafting), in 2 or more major coronary es, c) Or the combination of previous revascularisation in one major ry artery (percutaneous transluminal coronary angioplasty with or without stent, or coronary artery bypass grafting), and the presence of a significant stenosis in another major coronary artery (imaging evidence of at least 50% narrowing of the luminal diameter measured during a coronary angiography or a multi- sliced computed tomography raphy), Note: A e affecting the left main coronary artery is ered as a 2- vessel disease.

Evidence of a single vessel coronary artery disease with: a) The presence of a significant stenosis i.e. the imaging evidence of at least 50% narrowing of the luminal diameter of one major coronary artery in patients not subsequently successfully revascularised (measured during a coronary angiography or a multi-sliced computed aphy angiography) b) And at least one of the following (either (i) or (ii)): i. A positive non invasive stress test, confirmed by either: 1. A positive se tolerance test in ts without a te left bundle branch block, Wolff-Parkinson-White syndrome, or paced cular rhythm, or 2. A positive stress echocardiography showing regional systolic wall motion abnormalities, or 3. A positive scintigraphic test showing stress-induced ischemia, i.e. the development of transient perfusion defects during myocardial perfusion imaging; ii. Or patient discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection.

- Episode of unstable angina with confirmed evidence of coronary essel or single vessel disease as defined above.

- History of ischemic or haemorrhagic stroke - Presence of peripheral artery disease (symptomatic or not) documented by either: previous limb lasty, stenting or bypass surgery; or previous limb or foot amputation due to circulatory insufficiency; or angiographic evidence of significant (> 50%) peripheral artery stenosis in at least one limb; or evidence from a non-invasive measurement of icant (>50% or as reported as namically significant) peripheral artery is in at least one limb; or ankle brachial index of < 0.9 in at least one limb.

In a further aspect of the present invention, a patient having at risk of a cardiovascular e is d as having at least one of the following: a) Confirmed history of myocardial infarction, b) Unstable angina with documented multivessel coronary disease (at least two major coronary arteries in angiogram) or positive stress test (ST segment depression >= 2 mm or a positive r perfusion scintigram), Multivessel Percutaneous Coronary Intervention (PCI), Multivessel Coronary Artery By-pass Grafting (CABG), including with recurrent angina following surgery, History of ischemic or hemorrhagic stroke, Peripheral occlusive arterial disease (previous limb bypass surgery or percutaneous transluminal angioplasty; us limb or foot amputation due to circulatory insufficiency, angiographic or imaging detected (for e: ultrasound, Magnetic Resonance Imaging) significant vessel stenosis of major limb arteries).

W0 2014/161918 _ 35 _ Moreover, the present invention relates to a certain SGLT-2 inhibitor for use in a method of preventing, reducing the risk of or delaying the occurrence of cardiovascular events, such as cardiovascular death, (fatal or non-fatal) myocardial infarction (e.g. silent or non-silent Ml), (fatal or non-fatal) stroke, or hospitalisation (e.g. for acute ry syndrome, leg amputation, t) revascularization procedures, heart failure or for unstable angina pectoris), preferably in type 1 or type 2 diabetes patients, particularly in those type 1 or type 2 diabetes patients being at risk of cardiovascular events, such as type 1 or type 2 diabetes patients with one or more risk factors ed from A), B), C) and D): A) previous or existing vascular disease (such as e.g. myocardial infarction (e.g. silent or non-silent), coronary artery disease, percutaneous coronary intervention, coronary artery by- pass grafting, ischemic or hemorrhagic stroke, tive heart failure (e.g. NYHA class I, II, III or IV, e.g. left cular function <40%), or peripheral occlusive arterial disease), B) advanced age (such as e.g. age >/= 60-70 years), and C) one or more cardiovascular risk factors selected from - ed type 1 or type 2 diabetes mellitus (such as e.g. > 10 years on), - hypertension (such as e.g. > 130/80 mm Hg, or systolic blood pressure >140 mmHg or on at least one blood pressure lowering treatment), - current daily cigarette smoking, - dyslipidemia (such as e.g. atherogenic dyslipidemia, postprandial lipemia, or high level of LDL cholersterol (e.g. LDL cholesterol >/=130-135 mg/dL), low level of HDL cholesterol (e.g. <35-40 mg/dL in men or <45-50 mg/dL in women) and/or high level of triglycerides (e.g. >200-400 mg/dL) in the blood, or on at least one treatment for lipid abnormality), - obesity (such as e.g. abdominal and/or visceral y, or body mass index >/=45 kg/m2), - age >/= 40, - metabolic syndrome, hyperinsulinemia or insulin resistance, and - hyperuricemia, erectile ction, polycystic ovary syndrome, sleep apnea, or family history of vascular disease or cardiomyopathy in degree relative, D) one or more of the ing: - confirmed history of myocardial infarction, - unstable angina with documented multivessel coronary e or positive stress test, - multivessel Percutaneous Coronary Intervention, - multivessel Coronary Artery By-pass Grafting , - history of ischemic or hemorrhagic stroke, - peripheral occlusive arterial disease.

WO 61918 _ 36 _ said method comprising administering a therapeutically effective amount of the SGLT-2 tor, optionally in ation with one or more other therapeutic substances, to the patient.

In a further aspect, the present invention relates to a certain SGLT-2 inhibitor for use in a method of reducing arterial stiffness in a t. In one aspect, the patient is a patient ing to the present invention, in particular a patient with type 1 or type 2 es or pre-diabetes. Increased arterial stiffness is associated with an increased risk of cardiovascular events and the effect of empagliflozin on arterial stiffness is for example shown in the Examples hereinbelow.

The t invention further relates to a pharmaceutical composition comprising a certain SGLT-2 inhibitor as defined herein, empagliflozin, for use in the ies described herein.

When this invention refers to patients requiring treatment or prevention, it s primarily to treatment and prevention in humans, but the pharmaceutical composition may also be used accordingly in veterinary medicine in mammals. In the scope of this invention adult patients are preferably humans of the age of 18 years or older. Also in the scope of this invention, patients are adolescent humans, i.e. humans of age 10 to 17 years, preferably of age 13 to 17 years. It is assumed that in a adolescent tion the administration of the pharmaceutical composition according to the invention a very good HbA1c lowering and a very good lowering of the fasting plasma glucose can be seen. In addition it is assumed that in an adolescent population, in particular in overweight and/or obese patients, a pronounced weight loss can be observed.

As described hereinbefore by the stration of the pharmaceutical composition according to this invention and in particular in view of the high SGLT2 inhibitory activity of the SGLT2 inhibitors therein, excessive blood glucose is excreted through the urine of the patient, so that no gain in weight or even a reduction in body weight may result. Therefore, a treatment or prophylaxis according to this invention is advantageously suitable in those patients in need of such treatment or prophylaxis who are diagnosed of one or more of the conditions selected from the group consisting of ovenNeight and obesity, in particular class I obesity, class II obesity, class III obesity, al obesity and abdominal obesity. In addition a ent or prophylaxis according to this invention is advantageously suitable in those patients in which a weight increase is indicated. The ceutical composition as well as the methods according to the present invention allow a reduction of the HbA1c value W0 2014/161918 _ 37 _ to a desired target range, for example < 7 % and preferably < 6.5 %, for a higher number of patients and for a longer time of eutic ent compared with a corresponding monotherapy or a y using only two of the combination partners.

The pharmaceutical composition according to this invention and in particular the SGLT2 inhibitor therein exhibits a very good efficacy with regard to glycemic control, in particular in view of a reduction of fasting plasma e, postprandial plasma glucose and/or ylated obin (HbA1c). By administering a pharmaceutical composition according to this invention, a reduction of HbA1c equal to or greater than preferably 0.5 %, even more preferably equal to or greater than 1.0 % can be achieved and the reduction is particularly in the range from 1.0 % to 2.0 %.

Furthermore, the method and/or use according to this invention is advantageously applicable in those patients who show one, two or more of the following conditions: (a) a fasting blood glucose or serum glucose concentration greater than 100 mg/dL, in particular r than 125 mg/dL; (b) a postprandial plasma glucose equal to or greater than 140 mg/dL; (c) an HbA1c value equal to or greater than 6.5 %, in particular equal to or greater than 7.0 %, especially equal to or greater than 7.5 %, even more particularly equal to or greater than 8.0 %.

The present invention also discloses the use of the pharmaceutical composition for improving glycemic control in patients having type 1 or type 2 es or showing first signs of pre-diabetes. Thus, the invention also includes diabetes prevention. lf therefore a pharmaceutical composition according to this invention is used to improve the glycemic control as soon as one of the above-mentioned signs of pre-diabetes is present, the onset of manifest type 2 diabetes mellitus can be delayed or prevented.

Furthermore, the pharmaceutical ition according to this ion is particularly suitable in the treatment of patients with insulin dependency, i.e. in patients who are treated or othenNise would be treated or need treatment with an insulin or a derivative of insulin or a tute of insulin or a formulation comprising an insulin or a derivative or substitute thereof. These ts include patients with diabetes type 2 and patients with diabetes type Therefore, ing to a red embodiment of the present invention, there is ed a method for improving glycemic control and/or for reducing of fasting plasma glucose, of postprandial plasma glucose and/or of glycosylated hemoglobin HbA1c in a patient in need thereof who is diagnosed with impaired glucose tolerance (IGT), impaired fasting blood glucose (IFG) with insulin resistance, with metabolic syndrome and/or with type 2 or type 1 es mellitus characterized in that an SGLT2 inhibitor as defined hereinbefore and hereinafter is administered to the patient.

According to another preferred embodiment of the present invention, there is provided a method for improving gycemic control in patients, in particular in adult patients, with type 2 diabetes mellitus as an adjunct to diet and se.

It can be found that by using a pharmaceutical ition ing to this invention, an improvement of the glycemic control can be achieved even in those patients who have insufficient glycemic control in particular despite treatment with an antidiabetic drug, for e despite l ended or tolerated dose of oral monotherapy with metformin. A maximal recommended dose with regard to metformin is for example 2000 mg per day or 850 mg three times a day or any equivalent thereof.

Therefore, the method and/or use according to this invention is advantageously applicable in those ts who show one, two or more of the following conditions: (a) insufficient glycemic control with diet and exercise alone; (b) insufficient glycemic control despite oral monotherapy with metformin, in particular despite oral monotherapy at a maximal tolerated dose of metformin; (c) insufficient glycemic l despite oral monotherapy with another antidiabetic agent, in particular despite oral monotherapy at a maximal tolerated dose of the other abetic agent.

The lowering of the blood glucose level by the administration of an SGLT2 inhibitor ing to this invention is insulin-independent. Therefore, a pharmaceutical composition according to this invention is particularly suitable in the treatment of patients who are diagnosed having one or more of the following conditions - insulin resistance, - hyperinsulinemia, - pre-diabetes, - type 2 es mellitus, particular having a late stage type 2 diabetes mellitus, _ 3g _ - type 1 diabetes mellitus. rmore, a pharmaceutical composition according to this invention is particularly suitable in the treatment of patients who are diagnosed having one or more of the following conditions (a) obesity (including class I, II and/or ||| obesity), visceral obesity and/or abdominal obesity, (b) ceride blood level 2 150 mg/dL, (c) HDL-cholesterol blood level < 40 mg/dL in female patients and < 50 mg/dL in male (d) a ic blood pressure 2 130 mm Hg and a diastolic blood pressure 2 85 mm Hg, (e) a fasting blood glucose level 2 100 mg/dL.

It is assumed that patients sed with impaired glucose tolerance (IGT), impaired fasting blood e (IFG), with insulin resistance and/or with metabolic syndrome suffer from an sed risk of developing a cardiovascular disease, such as for example myocardial infarction, coronary heart disease, heart insufficiency, thromboembolic events. A glycemic control according to this invention may result in a reduction of the cardiovascular risks.

Furthermore, a pharmaceutical composition according to this ion is particularly suitable in the treatment of patients after organ transplantation, in particular those patients who are diagnosed having one or more of the following conditions (a) a higher age, in particular above 50 years, (b) male ; (c) ovenNeight, obesity (including class I, II and/or ||| obesity), visceral obesity and/or abdominal obesity, (d) ansplant diabetes, (e) immunosuppression therapy.

Furthermore, a pharmaceutical composition according to this invention is particularly suitable in the treatment of patients who are diagnosed having one or more of the following conditions: (a) hyponatremia, in particular chronical hyponatremia; (b) water intoxication; (c) water retention; (d) plasma sodium concentration below 135 .

The patient may be a diabetic or non-diabetic mammal, in particular human.

Furthermore, a pharmaceutical composition according to this invention is particularly suitable in the treatment of patients who are diagnosed having one or more of the following conditions: (a) high serum uric acid levels, in particular greater than 6.0 mg/dL (357 umol/L); (b) a history of gouty arthritis, in particular recurrent gouty arthritis; (c) kidney stones, in particular recurrent kidney stones; (d)a high propensity for kidney stone formation.

In certain embodiments, the patients which may be amenable to to the therapies of this ion may have or are at-risk of one or more of the following diseases, disorders or conditions: type 1 diabetes, type 2 diabetes, impaired glucose tolerance (IGT), impaired g blood glucose (IFG), hyperglycemia, postprandial lycemia, postabsorptive hyperglycemia, latent autoimmune diabetes in adults (LADA), overweight, obesity, dyslipidemia, ipidemia, hypercholesterolemia, hypertriglyceridemia, hyperNEFA—emia, postprandial |ipemia, hypertension, sclerosis, endothelial dysfunction, orosis, chronic systemic inflammation, non alcoholic fatty liver disease (NAFLD), polycystic ovarian syndrome, metabolic syndrome, nephropathy, micro- or macroalbuminuria, proteinuria, retinopathy, cts, neuropathy, learning or memory impairment, neurodegenerative or cognitive ers, cardiovascular diseases, tissue ischaemia, diabetic foot or ulcus, atherosclerosis, ension, endothelial dysfunction, dial infarction, acute coronary syndrome, unstable angina pectoris, stable angina pectoris, peripheral arterial occlusive disease, cardiomyopathy (including e.g. uremic cardiomyopathy), heart e, cardiac hypertrophy, heart rhythm disorders, vascular restenosis, stroke, (renal, cardiac, cerebral or hepatic) ischemia/reperfusion injuries, (renal, cardiac, cerebral or c) fibrosis, (renal, cardiac, cerebral or c) vascular remodeling; a diabetic disease, especially type 2 es, mellitus may be preferred (eg. as ying disease).

In a further embodiment, the patients which may be amenable to to the therapies of this invention have a diabetic disease, especially type 2 diabetes mellitus, and may have or are at-risk of one or more other diseases, disorders or ions, such as eg. selected from those mentioned immediately above.

In further ments, the present invention also relates to the effect of certain SGLT-2 inhibitors, in particular empagliflozin, on beta-cells and/or on the function of ells, for example in patients having latent autoimmune diabetes in adults (LADA). _ 41 _ Accordingly, in one embodiment, the present invention relates to certain SGLT-2 inhibitors, in particular empagliflozin, for use in preventing, slowing, delaying or treating the degeneration of pancreatic beta cells and/or the decline of the functionality of pancreatic beta cells and/or for improving and/or restoring the functionality of pancreatic beta cells and/or restoring the functionality of atic insulin secretion in a patient having latent autoimmune diabetes in adults (LADA).

In a further embodiment, the present invention relates to certain SGLT-2 inhibitors, in particular empagliflozin, for use in preserving pancreatic beta cells and/or their on in a patient having latent autoimmune diabetes in adults (LADA).

In a further embodiment, the present invention s to certain SGLT-2 tors, in particular empagliflozin, for use in stimulating and/or protecting the functionality of pancreatic insulin secretion in a patient having latent autoimmune diabetes in adults (LADA).

Usually three criteria are needed led for diagnosis of LADA: 1) adult age at onset of diabetes (> 30 years), 2) the presence of ating islet autoantibodies (markers of beta cell autoimmunity to guish LADA from T2DM, e.g. islet cell antibodies (ICA, against cytoplasmic proteins in the beta cell, islet-cell cytoplasm), antibodies to glutamic acid decarboxylase (GAD-65, anti- GAD), insulin autoantibodies (IAA), and/or lA—2A antibodies to the intracytoplasmatic domain of the tyrosine phosphatase-like protein lA—2), and 3) lack of a requirement for insulin for at least 6 months after diagnosis (to guish LADA from classic T1 DM).

However, alternative definitions of LADA include GAD (glutamic acid oxylase) antibody titer 2 0.08 U/mL and 1) lifestyle and oral therapy or 2) insulin treatment started later than 12 months after diagnosis or 3) insulin therapy d before 12 months after diagnosis, but with fasting C-peptide levels > 150 pmol/l.

C-peptide originates from proinsulin and is produced in the body along with insulin. It is an ed ker for proof of ell preservation. Persons with LADA typically have low, although sometimes moderate, levels of C-peptide as the disease progresses.

One prerequisite in the definition is the presence of one or more circulating autoantibodies.

For this s it is sometimes argued that LADA is just a "low-titer T1 DM condition". _ 42 _ However, the LADA population often shares phenotypical traits with T2DM, more so than with T1 DM; therefore LADA etiologically may represent a unique disease entity that is characterized by a more rapid decline of B-cell function than common T2DM.

It has been demonstrated, in several studies, that insulin ency occurs at higher rate in LADA than in subjects with common T2DM.

Accordingly, in one aspect, a patient having LADA according to the present invention is a patient in whom one or more autoantibodies selected from GAD (GAD-65, anti-GAD), ICA, lA—2A, ZnT8 (anti-ZnT8) and IAA are present, and in one aspect, in a method or use according to the present invention a t having LADA is a patient in whom one or more autoantibodies selected from GAD (GAD-65, anti-GAD), ICA, lA—2A, ZnT8 (anti-ZnT8).

One assumes that the LADA prevalence in a general type 2 diabetes population is at least 5- %. Moreover, adults with LADA are frequently initially misdiagnosed as having type 2 diabetes, based on age; not etiology. In a survey conducted by lia’s Type 1 Diabetes Network, one third of all lians with type 1 diabetes reported being initially misdiagnosed as having the more common type 2 diabetes mellitus.

Currently, there is no "gold standard" for LADA treatment or management. In general, the treatment of LADA should focus not only on controlling glycemia and preventing the onset of any complications, but also allow preservation of residual beta cell function. Insulin y in LADA is often cious; but might be of most t in patients with both a high titer of GAD (> 10 U/mL) and preserved insulin ion (C-peptide > 10 . This also seems to apply to thiazolidinediones (glitazones), in particular if combined with insulin when islet beta cell function is ved. Sulfonylureas (SUs) (and glinides) have in some studies been shown to be detrimental on beta cell function in LADA. This is ted by that metabolic control by SUs when compared to insulin also is often less.

Accordingly, in a further embodiment, the present invention relates to certain SGLT-2 inhibitors, in particular empagliflozin, for use in treating and/or preventing LADA (latent autoimmune diabetes of adults), particularly in those patients having LADA in whom one or more autoantibodies selected from GAD (GAD-65, anti-GAD), ICA, lA—2A, ZnT8 (anti-ZnT8) and lAA are t.

Within the scope of the present invention it has now been found that certain SGLT-2 inhibitors as defined herein, optionally in combination with one or more other therapeutic nces (e.g. selected from those described herein), as well as pharmaceutical combinations, compositions or combined uses according to this invention of such SGLT-2 inhibitors as defined herein have properties, which make them suitable for the purpose of this ion and/or for fulfilling one or more of above needs.

The effect of empagliflozin on cardiovascular diseases, in particular on the risk of a cardiovascular event, for example such as d herein, is for e determined as described in the Examples hereinbelow.

The effect of empagliflozin on beta-cells and/or on the function of beta-cells is for example determined as described in the Examples hereinbelow.

The present invention thus relates to a certain SGLT-2 inhibitor as defined herein, preferably empagliflozin, for use in the therapies described herein. rmore, it can be found that the stration of a pharmaceutical composition according to this invention results in no risk or in a low risk of hypoglycemia. Therefore, a treatment or prophylaxis according to this invention is also advantageously possible in those patients g or having an increased risk for hypoglycemia.

A pharmaceutical composition according to this invention is ularly le in the long term treatment or laxis of the diseases and/or conditions as described before and hereinafter, in particular in the long term glycemic control in patients with type 2 diabetes mellitus.

The term "long term" as used hereinbefore and hereinafter indicates a treatment of or administration in a patient within a period of time longer than 12 weeks, preferably longer than 25 weeks, even more preferably longer than 1 year.

Therefore, a ularly red embodiment of the present invention provides a method for therapy, preferably oral therapy, for improvement, especially long term improvement, of glycemic control in patients with type 2 diabetes mellitus, especially in patients with late stage type 2 diabetes mellitus, in particular in patients additionally diagnosed of overweight, obesity (including class |, class II and/or class III obesity), visceral obesity and/or abdominal obesity.

WO 61918 _ 44 _ It will be appreciated that the amount of the pharmaceutical composition according to this invention to be administered to the patient and required for use in treatment or laxis according to the present invention will vary with the route of administration, the nature and severity of the condition for which treatment or prophylaxis is required, the age, weight and condition of the patient, concomitant medication and will be ultimately at the discretion of the attendant physician. In general, however, the SGLT2 inhibitor according to this invention is included in the pharmaceutical composition or dosage form in an amount sufficient that by its administration the glycemic control in the t to be treated is improved.

For the treatment of hyperuricemia or hyperuricemia associated conditions the SGLT2 inhibitor according to this invention is included in the pharmaceutical composition or dosage form in an amount sufficient that is sufficient to treat hyperuricemia without disturbing the patient's plasma glucose homeostasis, in particular without inducing hypoglycemia.

For the treatment or prevention of kidney stones the SGLT2 inhibitor according to this invention is included in the pharmaceutical composition or dosage form in an amount sufficient that is sufficient to treat or prevent kidney stones t disturbing the patient's plasma glucose homeostasis, in particular without inducing ycemia.

For the treatment of hyponatremia and associated ions the SGLT2 inhibitor according to this invention is included in the pharmaceutical composition or dosage form in an amount ient that is sufficient to treat hyponatremia or the associated conditions without disturbing the t's plasma glucose homeostasis, in ular without inducing hypoglycemia.

In the ing preferred ranges of the amount of the SGLT2 inhibitor to be employed in the pharmaceutical composition and the methods and uses according to this invention are described. These ranges refer to the s to be administered per day with respect to an adult patient, in particular to a human being, for example of approximately 70 kg body weight, and can be adapted accordingly with regard to an administration 2, 3, 4 or more times daily and with regard to other routes of administration and with regard to the age of the t.

Within the scope of the t invention, the pharmaceutical composition is preferably administered orally. Other forms of administration are possible and described hereinafter.

Preferably the one or more dosage forms comprising the SGLT2 inhibitor is oral or usually well known.

W0 2014/161918 In general, the amount of the SGLT2 inhibitor in the pharmaceutical composition and methods according to this invention is preferably the amount usually recommended for a monotherapy using said SGLT2 inhibitor.

The preferred dosage range of the SGLT2 inhibitor is in the range from 0.5 mg to 200 mg, even more preferably from 1 to 100 mg, most preferably from 1 to 50 mg per day. In one aspect, a preferred dosage of the SGLT2 inhibitor empagliflozin is 10 mg or 25 mg per day.

The oral administration is red. Therefore, a pharmaceutical composition may comprise the hereinbefore mentioned amounts, in particular from 1 to 50 mg or 1 to 25 mg. Particular dosage ths (e.g. per tablet or e) are for example 1, 2.5, 5, 7.5, 10, 12.5, 15, 20, or 50 mg of the SGLT2 inhibitor, in particular empagliflozin. In one aspect, a ceutical composition comprises 10 mg or 25 mg of empagliflozin. The application of the active ingredient may occur up to three times a day, preferably one or two times a day, most ably once a day.

A ceutical composition which is present as a separate or multiple dosage form, preferably as a kit of parts, is useful in combination therapy to flexibly suit the individual therapeutic needs of the patient.

According to a first embodiment a preferred kit of parts comprises a containment containing a dosage form comprising the SGLT2 inhibitor and at least one pharmaceutically acceptable carrier.

A further aspect of the present invention is a manufacture comprising the pharmaceutical composition being present as separate dosage forms according to the present ion and a label or package insert comprising ctions that the separate dosage forms are to be administered in combination or alternation.

According to a first embodiment a manufacture comprises (a) a pharmaceutical composition comprising a SGLT2 inhibitor according to the present invention and (b) a label or package insert which comprises ctions that the medicament is to be administered.

The desired dose of the ceutical composition according to this invention may iently be presented in a once daily or as divided dose administered at appropriate intervals, for example as two, three or more doses per day.

WO 61918 The pharmaceutical composition may be formulated for oral, rectal, nasal, topical (including buccal and sublingual), transdermal, vaginal or parenteral (including intramuscular, sub- cutaneous and intravenous) administration in liquid or solid form or in a form suitable for administration by inhalation or insufflation. Oral administration is preferred. The formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active ingredient with one or more pharmaceutically able carriers, like liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired formulation.

The pharmaceutical ition may be formulated in the form of tablets, granules, fine granules, powders, capsules, caplets, soft capsules, pills, oral solutions, syrups, dry , chewable tablets, troches, effervescent tablets, drops, suspension, fast dissolving tablets, oral fast-dispersing tablets, etc..

The pharmaceutical composition and the dosage forms preferably comprises one or more pharmaceutical acceptable carriers which must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not rious to the recipient thereof. Examples of pharmaceutically acceptable carriers are known to the one skilled in the art.

Pharmaceutical compositions suitable for oral administration may conveniently be presented as discrete units such as capsules, including soft n es, cachets or tablets each ning a ermined amount of the active ingredient; as a powder or es; as a solution, a suspension or as an emulsion, for example as syrups, elixirs or self-emulsifying delivery systems (SEDDS). The active ingredients may also be presented as a bolus, electuary or paste. Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents. The s may be coated according to s well known in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other le vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, fying agents, non-aqueous vehicles (which may include edible oils), or preservatives.

W0 61918 2014/056655 The pharmaceutical composition according to the invention may also be formulated for parenteral administration (e.g. by injection, for example bolus ion or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredients may be in powder form, obtained by c isolation of sterile solid or by lisation from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.

Pharmaceutical compositions suitable for rectal administration wherein the carrier is a solid are most preferably presented as unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art, and the suppositories may be conveniently formed by admixture of the active compound(s) with the softened or melted carrier(s) followed by chilling and shaping in moulds.

The pharmaceutical compositions and methods according to this invention show advantageous effects in the ent and prevention of those diseases and conditions as described hereinbefore. Advantageous effects may be seen for example with respect to efficacy, dosage th, dosage frequency, pharmacodynamic properties, pharmacokinetic ties, fewer adverse effects, convenience, compliance, etc..

Methods for the manufacture of SGLT2 inhibitors according to this invention and of prodrugs thereof are known to the one skilled in the art. Advantageously, the compounds ing to this invention can be prepared using synthetic methods as described in the literature, including patent applications as cited hereinbefore. Preferred methods of manufacture are described in the and . With regard to empagliflozin an advantageous lline form is described in the international patent ation which hereby is incorporated herein in its entirety.

The active ients may be present in the form of a pharmaceutically acceptable salt.

Pharmaceutically acceptable salts include, without being restricted thereto, such as salts of inorganic acid like hydrochloric acid, ic acid and phosphoric acid; salts of c ylic acid like oxalic acid, acetic acid, citric acid, malic acid, benzoic acid, maleic acid, fumaric acid, tartaric acid, succinic acid and glutamic acid and salts of organic sulfonic acid like methanesulfonic acid and enesulfonic acid. The salts can be formed by combining _ 48 _ the compound and an acid in the appropriate amount and ratio in a solvent and decomposer.

They can be also obtained by the cation or anion exchange from the form of other salts.

The active ingredients or a ceutically acceptable salt thereof may be present in the form of a solvate such as a hydrate or alcohol adduct.

Pharmaceutical compositions or combinations for use in these therapies comprising the SGLT-2 inhibitor as d herein optionally er with one or more other active substances are also contemplated.

Further, the present ion relates to the SGLT—2 inhibitors, optionally in combination with one, two or more further active agents, each as defined herein, for use in the therapies as described herein.

Further, the present invention relates to the use of the SGLT-2 tors, ally in combination with one, two or more further active agents, each as defined herein, for preparing pharmaceutical compositions which are suitable for the ent and/or tion purposes of this invention.

The present ion further relates to a pharmaceutical composition comprising a certain SGLT-2 inhibitor as defined herein, preferably empagliflozin, and metformin, for use in the ies described herein.

The present invention further relates to a combination comprising a certain SGLT-2 inhibitor (particularly empagliflozin) and one or more other active substances selected from those mentioned herein, e.g. selected from other antidiabetic substances, active nces that lower the blood sugar level, active substances that lower the lipid level in the blood, active substances that raise the HDL level in the blood, active substances that lower blood pressure, active substances that are indicated in the treatment of atherosclerosis or obesity, antiplatelet agents, anticoagulant agents, and vascular endothelial protective agents, e.g. each as described herein; particularly for simultaneous, separate or sequential use in the therapies described herein.

The present invention further relates to a combination comprising a n SGLT-2 inhibitor (particularly iflozin) and one or more other antidiabetics selected from the group consisting of metformin, a sulphonylurea, nateglinide, repaglinide, a thiazolidinedione, a 2014/056655 PPAR-gamma-agonist, an alpha-glucosidase inhibitor, insulin or an insulin analogue, GLP-1 or a GLP-1 analogue and a DPP-4 inhibitor, particularly for simultaneous, separate or sequential use in the ies described herein.

The present invention further relates to a method for treating and/or preventing metabolic disorders, especially type 2 diabetes mellitus and/or conditions related thereto (e.g. diabetic complications) comprising the combined (e.g. simultaneous, separate or sequential) administration of an effective amount of one or more other antidiabetics selected from the group consisting of metformin, a sulphonylurea, nateglinide, repaglinide, a PPAR-gamma- agonist, an alpha-glucosidase inhibitor, insulin or an insulin analogue, GLP-1 or a GLP-1 ue and a DPP-4 tor, to the patient cularly human patient) in need thereof, such as e.g. a patient as described herein, including at-risk patient groups.

The t invention further relates to therapies or therapeutic methods described , such as e.g. a method for treating and/or preventing metabolic disorders, especially type 2 diabetes mellitus and/or conditions related thereto (e.g. ic complications), comprising administering a therapeutically ive amount of empagliflozin and, optionally, one or more other therapeutic agents, such as e.g. antidiabetics selected from the group consisting of metformin, a sulphonylurea, inide, repaglinide, a PPAR-gamma-agonist, an alpha- glucosidase inhibitor, insulin or an insulin analogue, GLP-1 or a GLP-1 analogue and a DPP- 4 inhibitor, to the patient (particularly human patient) in need thereof, such as e.g. a patient as described herein (e.g. k patient as described herein).

Within this invention it is to be understood that the ations, compositions or ed uses according to this invention may envisage the simultaneous, sequential or separate administration of the active components or ingredients.

In this t, "combination" or "combined" within the meaning of this invention may include, without being limited, fixed and non-fixed (e.g. free) forms (including kits) and uses, such as e.g. the simultaneous, sequential or separate use of the components or ingredients.

The combined administration of this invention may take place by stering the active components or ingredients together, such as e.g. by administering them simultaneously in one single or in two separate formulations or dosage forms. Alternatively, the administration may take place by stering the active components or ingredients tially, such as e.g. successively in two separate formulations or dosage forms.

For the combination therapy of this invention the active components or ingredients may be administered separately (which implies that they are formulated tely) or ated altogether (which implies that they are formulated in the same preparation or in the same dosage form). Hence, the administration of one element of the combination of the present invention may be prior to, concurrent to, or subsequent to the administration of the other element of the combination.

Unless otherwise noted, combination therapy may refer to first line, second line or third line therapy, or initial or add-on combination therapy or replacement therapy.

The present invention further relates to a certain SGLT-2 inhibitor as defined , preferably iflozin, in combination with metformin, for use in the therapies described herein.

Metformin is usually given in doses varying from about 500 mg to 2000 mg up to 2500 mg per day using various dosing regimens from about 100 mg to 500 mg or 200 mg to 850 mg (1-3 times a day), or about 300 mg to 1000 mg once or twice a day, or delayed-release metformin in doses of about 100 mg to 1000 mg or preferably 500 mg to 1000 mg once or twice a day or about 500 mg to 2000 mg once a day. Particular dosage ths may be 250, 500, 625, 750, 850 and 1000 mg of min hydrochloride.

For children 10 to 16 years of age, the recommended starting dose of metformin is 500 mg given once daily. If this dose fails to produce adequate results, the dose may be increased to 500 mg twice daily. Further increases may be made in ents of 500 mg weekly to a maximum daily dose of 2000 mg, given in divided doses (e.g. 2 or 3 divided doses).

Metformin may be administered with food to decrease nausea.

An example of a DPP-4 inhibitor is linagliptin, which is usually given in a dosage of 5 mg per day.

A dosage of tazone is usually of about 1-10 mg, 15 mg, 30 mg, or 45 mg once a day.

Rosiglitazone is y given in doses from 4 to 8 mg once (or divided twice) a day (typical dosage strengths are 2, 4 and 8 mg).

Glibenclamide (glyburide) is usually given in doses from 2.5-5 to 20 mg once (or divided twice) a day (typical dosage strengths are 1.25, 2.5 and 5 mg), or micronized glibenclamide in doses from 0.75-3 to 12 mg once (or divided twice) a day (typical dosage strengths are 1.5, 3, 4.5 and 6 mg). ide is usually given in doses from 2.5 to 10-20 mg once (or up to 40 mg divided twice) a day (typical dosage strengths are 5 and 10 mg), or extended-release glibenclamide in doses from 5 to 10 mg (up to 20 mg) once a day (typical dosage strengths are 2.5, 5 and 10 mg).

Glimepiride is usually given in doses from 1-2 to 4 mg (up to 8 mg) once a day al dosage strengths are 1, 2 and 4 mg).

The non-sulphonylurea insulin secretagogue nateglinide is y given in doses from 60 to 120 mg with meals (up to 360 mg/day, typical dosage strengths are 60 and 120 mg); repaglinide is usually given in doses from 0.5 to 4 mg with meals (up to 16 mg/day, typical dosage strengths are 0.5, 1 and 2 mg). A dual combination of repaglinide/metformin is available in dosage strengths of 1/500 and 2/850 mg.

In one aspect of the t invention, the one or more other therapeutic substances are active substances that lower the blood sugar level, active substances that lower the lipid level in the blood, active substances that raise the HDL level in the blood, active substances that lower blood re, active substances that are indicated in the treatment of atherosclerosis or obesity, antiplatelet , anticoagulant agents, and vascular endothelial protective agents.

In one , the present invention provides a method of treatment comprising fying a patient with type 2 diabetes treated with a ity of medications to treat a cardiovascular disease, administering empagliflozin to said patient; and reducing the number, dosage or regimen of medications to treat a cardiovascular disease in said patient, in particular while continuing to administer iflozin to the patient. In one embodiment, the method further comprises monitoring the cardiac health of said patient.

Examples of medications to treat a cardiovascular disease include medications that lower blood, such as for example beta-blockers, diuretics, calcium channel blockers, Angiotensin- Converting Enzyme (ACE) inhibitors and angiotensin II receptor rs (ARBs). 2014/056655 Examples of medications that lower blood pressure are beta-blockers such as acebutolol, atenolol, Betaxolol, bisoprolol, celiprolol, metoprolol, nebivolol, Propranolol, Timolol and carvedilol; the dosage(s) of some of these medications are for example shown below: . Acebutolol (Sectral), 200 or 400 mg of acebutolol as the hydrochloride salt . Atenolol min), 25, 50 and 100 mg tablets for oral administration . lol (Kerlone), 10-mg and 20-mg tablets for oral administration . Bisoprolol/hydrochlorothiazide (Ziac), 2.5/6 mg, 5/6.25 mg, 10/6.25 mg . Bisoprolol (Zebeta), 5 and 10 mg tablets for oral administration . Metoprolol (Lopressor, Toprol XL), 50- and 100-mg tablets for oral administration and in 5-mL ampuls for intravenous administration . Propranolol al), 10 mg, 20 mg, 40 mg, 60 mg, and 80 mg s for oral administration . Timolol (Blocadren), 5 mg, 10 mg or 20 mg timolol maleate for oral administration.

Examples of medications that lower blood pressure are diuretics such as Bumetanide, hydrochlorothiazide, chlortalidon, Chlorothiazide, Hydro-chlorothiazide, xipamide, lndapamide, furosemide, piretanide, torasemide, spironolactone, eplerenone, amiloride and triamterene; for example these medications are thiazide diuretics, eg chlorthalidone, HCT, loop diuretics, eg furosemide, torasemide or potassium-sparing diuretics, eg eplerenone, or combination thereof; the dosage(s) of some of these tions are for example shown below: . Amiloride (Midamor), 5 mg of anhydrous amiloride HCI . Bumetanide (Bumex), available as scored tablets, 0.5 mg (light green), 1 mg (yellow) and 2 mg (peach) for oral administration . Chlorothiazide(Diuril), . Chlorthalidone(Hygroton) . Furosemide (Lasix) . Hydro-chlorothiazide (Esidrix, Hydrodiuril) . lndapamide (Lozol) and olactone (Aldactone) . Eplerenone (lnspra) es of medications that lower blood re are calcium channel rs such as amlodipine, nifedipine, nitrendipine, nisoldipine, nicardipine, pine, lacidipine, lercanipidine, manidipine, isradipine, ipine, verapamil, gallopamil and diltiazem; es of medications that lower blood pressure are Angiotensin-Converting Enzyme (ACE) inhibitors such as Benazepril, Captopril, ramipril, lisinopril, Moexipril, cilazapril, quinapril, captopril, enalapril, benazepril, perindopril, fosinopril and trandolapril; the dosage(s) of some of these medications are for e shown below: Benazepril (Lotensin), 5 mg, 10 mg, 20 mg, and 40 mg for oral administration Captopril (Capoten), 12.5 mg, 25 mg, 50 mg, and 100 mg as scored s for oral administration ril (Vasotec), 2.5 mg, 5 mg, 10 mg, and 20 mg s for oral administration Fosinopril (Monopril), for oral administration as 10 mg, 20 mg, and 40 mg tablets Lisinopril (Prinivil, Zestril), 5 mg, 10 mg, and 20 mg tablets for oral administration Moexipril (Univasc), 7.5 mg and 15 mg for oral administration Perindopril (Aceon), 2 mg, 4 mg and 8 mg strengths for oral administration Quinapril (Accupril), 5 mg, 10 mg, 20 mg, or 40 mg of ril for oral administration Ramipril (Altace), 1.25 mg, 2.5 mg, 5, mg, 10 mg Trandolapril (Mavik) 1 mg, 2 mg, or4 mg of trandolapril for oral administration Examples of medications that lower blood pressure are angiotensin II receptor blockers (ARBs) such as telmisartan, candesartan, valsartan, losartan, irbesartan, olmesartan, azilsartan and rtan; the dosage(s) of some of these medications are for example shown below: Candesartan (Atacand), 4 mg, 8 mg, 16 mg, or 32 mg of candesartan cilexetil Eprosartan (Teveten), 400 mg or 600 mg lrbesartan (Avapro), 75 mg, 150mg, or 300 mg of irbesartan.

Losartan (Cozaar), 25 mg, 50 mg or 100 mg of losartan potassium Telmisartan (Micardis) , 40 5 mg, 80 mg/12.5 mg, and 80 mg/25 mg telmisartan and hydrochlorothiazide Valsartan (Diovan) , 40 mg, 80 mg, 160 mg or 320 mg of valsartan A dosage of telmisartan is usually from 20 mg to 320 mg or 40 mg to 160 mg per day.

Further ments, features and advantages of the present invention may become nt from the following examples. The following examples serve to illustrate, by way of example, the principles of the invention without restricting it.

Examples Example 1: Effects of SGLT2 inhibition on oxidative stress, vessel wall thickness and collagen content, and endothelial dysfunction in STZ-induced Diabetes meIIitus (Type I) in rat.

Type I diabetes in Wistar rats (8 weeks old, 250-300 g) are induced by a single i.v. injection of STZ (60 mg/kg). The blood glucose level is ed 3 days after STZ injection (to test whether diabetes was induced) and on the day of ice. One week after injection empagliflozin -i) was administered with drinking water for additional 7 weeks (10 and d p.o.). Treatment with empagliflozin showed a distinct reduction of blood glucose levels in diabetic rats without influence on loss of weight gain. Isometric tension recordings showed an empagliflozin-dependent normalization of endothelial function in diabetic animals and reduced oxidative stress in aortic vessels and blood, examined by DHE staining of aortic cryosections and PDBu/zymosanA—stimulated chemiluminescence, respectively. Additionally, a tendency of increased NADPH-oxidase activity in heart and a significant reduction of ALDH-2 activity in the liver were observed in diabetic animals, reflecting oxidative stress diminution triggered by iflozin y. The results are shown in Figures 1-13.

Figure 1: Shows the effect of Empagliflozin on weight gain, blood glucose and glycated hemoglobin (HbA1C) at low dose kg) and high dose (30mg/kg) given in drinking water.

Figure 2: A: Endothelial dependant vasorelaxation. This figure shows the improvement of endothelial function measured with ed aortic rings after 7 weeks of ent.

B: Endothelial independent vasorelaxation obtain with glyceryl trinitrate (GTN) a NO donor.

This figure shows the capacity of all vessel walls to vasorelax independently of the endothelium demonstrating the absence of rious effect of the treament on smooth muscle cells.

Figures 3-9: Quantification of reactive oxygen species of (ROS) from leukocyte upon stimulation with zymosan A (ZymA). After 7 weeks of treament, ROS production in blood is reduced either with the low or high dose of empagliflozin to level close to none diabetic animal.

Figure 10: Shows that the NADPH oxidase activity in the cardiac tissue, an important source of xide is diminished with iflozin treatment.

Figure 11: Shows that the reduction of ALDH-2 activity in diabetic STZ animal is partly restored with empagliflozin treatment. _ 55 _ Figure 12A and 12B: Shows that the superoxide ion in the s of diabetic animals is reduced. Figure 12A shows results with a partial set of animals, figure 128 shows results with all animals.

Figure 13A—D: Shows the level of plasmatic cholesterol, triglycerides, insulin and eron y in STZ diabetic rats compared to normal rat and in diabetic rat treated with iflozin.

While empagliflozin restore insulin level, the elevation of interferon y (a marker of mation) in diabetic rats is highly diminished or supressed with empagliflozin treatment.

Aortic wall thickness and collagen content were also measured microscopically after sirius red staining. Aortic segments were fixed in parafomaldehyde (4%) and paraffin-embedded.

Sirius red staining for vascular fibrosis was performed with paraffin-embedded samples of aortic tissue upon de-paraffination. AftenNards the nuclei were prestained with hemalum.

Then samples were stained for 1 hour in 0.1% with Sirius red solution containing saturated picric acid (1.2%). Finally, tissue samples were dehydrated with 70%, 96% and 100% isopropanol and coverslipped with a on of polymers in xylene. 60-70 measurements were made per sample, n=6-7 animals/groups. The results are shown in s 16A and 168.

Figure 16A and 16B: Microscopic determination of aortic wall thickness and collagen content by sirius red staining of aortic paraffinated sections. Quantification e 16A) and representative microscope images (figure 16B). Aortic wall thickness and collagen t was slightly increased in diabetic rats and was normalized by empagliflozin treatment.

Example 2: ement of hourly blood pressure.

Empagliflozin (10 mg and 25 mg) was administered orally once daily over 12 weeks in hypertensive patients with type 2 diabetes mellitus. The change from baseline in hourly mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured over a 24- hour period afer 12 weeks of treatment compared to the placebo group and is shown in Figures 14 and 15.

Example 3: ent of ts with type 2 diabetes mellitus with elevated cardiovascular risk.

The longterm impact on cardiovascular morbidity and mortality and relevant efficacy parameters (e.g. HbA1c, fasting plasma glucose, treatment sustainability) of treatment with W0 2014/161918 2014/056655 _ 56 _ empagliflozin in a relevant population of patients with type 2 diabetes mellitus is investigated as follows: Type 2 diabetes patient with elevated risk of cardiovascular events, e.g. as defined below, are treated over a lengthy period (e.g. for between approximately 6 and 8 years) with empagliflozin (optionally in combination with one or more other active substances, e.g. such as those described herein) and compared with patients who have been treated with a placebo on standard of care background tion.

Empagliflozin is administered orally once daily (10 mg/daily or 25 mg/daily). Patients are diagnosed with type 2 diabetes mellitus, are on diet and exercise regimen and are drug- na'I've or pre-treated with any background therapy. Patients have a HbA1C of 27.0% and s % for patients on background therapy or HbA1C 27.0% and S 9.0% for drug-nai've patients.

Patients with an ed cardiovascular risk are defined as having at least one of the following: - Confirmed history of myocardial infarction; or - Evidence of multivessel ry artery disease, in 2 or more major coronary arteries, irrespective of the revascularization status, Le. a) Either the presence of a significant stenosis (imaging evidence of at least 50% narrowing of the l diameter measured during a ry raphy or a multi-sliced computed tomography angiography), in 2 or more major coronary arteries, b) Or a previous revascularisation (percutaneous transluminal coronary lasty with or without stent, or coronary artery bypass grafting), in 2 or more major coronary arteries, c) Or the ation of previous revascularisation in one major coronary artery (percutaneous transluminal ry angioplasty with or t stent, or coronary artery bypass ng), and the presence of a significant stenosis in another major coronary artery (imaging ce of at least 50% narrowing of the luminal diameter measured during a coronary raphy or a multi-sliced computed tomography angiography), Note: A disease affecting the left main coronary artery is considered as a 2-vessel disease.

- Evidence of a single vessel coronary artery disease with: a) The presence of a significant stenosis i.e. the imaging evidence of at least 50% narrowing of the luminal diameter of one major coronary artery in patients not _ 57 _ subsequently successfully revascularised red during a coronary angiography or a multi-sliced computed tomography raphy) b) And at least one of the following (either (i) or (ii)): i. A ve non invasive stress test, confirmed by either: 1. A positive exercise tolerance test in ts without a complete left bundle branch block, Wolff-Parkinson-White syndrome, or paced ventricular rhythm, 2. A positive stress echocardiography showing regional systolic wall motion abnormalities, or 3. A positive scintigraphic test showing stress-induced ischemia, i.e. the development of transient perfusion defects during myocardial perfusion imaging; ii. Or patient discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to ion.

- Episode of unstable angina with confirmed evidence of coronary multivessel or single vessel disease as defined above.

- History of ischemic or haemorrhagic stroke - Presence of peripheral artery disease (symptomatic or not) documented by either: previous limb angioplasty, stenting or bypass surgery; or us limb or foot amputation due to circulatory insufficiency; or angiographic evidence of significant (> 50%) peripheral artery stenosis in at least one limb; or evidence from a non-invasive measurement of significant (>50% or as reported as hemodynamically significant) peripheral artery is in at least one limb; or ankle brachial index of < 0.9 in at least one limb.

Criteria for efficacy are for example change from baseline in: HbA1c, Fasting Plasma Glucose (FPG), weight, waist circumference and blood re at weeks 12, 52, once a year, and end of study.

The time to first occurrence of any of the adjudicated components of the primary composite Major e Cardiovascular Event (MACE) endpoint (cardiovascular death (including fatal stroke and fatal myocardial infarction), non fatal stroke, nonfatal myocardial infarction (MI) is determined in patients d with empagliflozin compared to o.

The time to the first occurrence of the following cated events (treated as a composite): CV death (including fatal stroke and fatal Ml), non-fatal Ml (excluding silent Ml), non-fatal W0 2014/161918 _ 58 _ stroke and hospitalization for unstable angina pectoris is also ined in patients treated with empagliflozin compared to placebo.

Also determined are the occurrence of and time to each of the following events: . Silent MI. 0 Heart failure requiring hospitalization . New onset nuria defined as ACR 2 30 mg/g . New onset macroalbuminuria 2300 mg/g.

. Composite microvascular outcome defined as: 1) Need for l photocoagulation 2) Vitreous rhage 3) Diabetes-related ess 4) New or worsening nephropathy d as: 4a) New onset of macroalbuminuria; or 4b) Doubling of serum creatinine level accompanied by an eGFR (based on modification of diet in renal disease (MDRD) formula) 5 45 mL/min/1.73m2; or 4c) Need for continuous renal replacement therapy; or d) death due to renal disease.

Also determined are the occurrence of and time to each of the following adjudicated events: CV death (including fatal stroke and fatal Ml) non-fatal Ml non-fatal stroke Hospitalization for unstable angina All cause mortality ry revascularization procedures.

Example 4: Treatment of type 2 diabetes mellitus Treating patients with type 2 diabetes mellitus with empagliflozin, in addition to producing an acute ement in the glucose metabolic situation, prevents a deterioration in the metabolic ion in the long term. This can be observed is patients are treated for a longer period, e.g. 3 months to 1 year or even 1 to 6 years, with a combination according to the invention and are compared with patients who have been treated with other antidiabetic and/ or esity medicaments. There is evidence of therapeutic success compared with other treatments if no or only a slight increase in the fasting glucose and/or HbA1c value is observed. Further evidence of therapeutic success is obtained if a significantly smaller tage of the patients treated with a combination according to the invention, compared with patients who have received another ent, undergo a deterioration in the glucose W0 2014/161918 2014/056655 _ 5g _ metabolic position (e.g. an increase in the HbA1c value to >6.5% or >7%) to the point where treatment with an (additional) oral antidiabetic medicament or with insulin or with an insulin analogue is indicated.

Example 5: Treatment of n resistance In clinical s running for different lengths of time (e.g. 2 weeks to 12 months) the success of the treatment is checked using a hyperinsulinaemic euglycaemic glucose clamp study. A significant rise in the glucose infusion rate at the end of the study, compared with the initial value or compared with a placebo group, or a group given a ent therapy, proves the efficacy of a treatment according to the invention in the treatment of insulin ance.

Example 6: Treatment of hyperglycaemia In clinical studies running for different lengths of time (e.g. 1 day to 24 months) the success of the treatment in patients with hyperglycaemia is checked by determining the fasting glucose or sting glucose (e.g. after a meal or a loading test with oGTT or a defined meal). A icant fall in these glucose values during or at the end of the study, compared with the initial value or compared with a placebo group, or a group given a different therapy, proves the efficacy of a combination treatment according to the invention in the treatment of hyperglycaemia.

Example 7: Effect of empagliflozin versus iride on beta-cell function In a Phase III study the effects of empagliflozin and the SU glimepiride as second-line therapy are compared in patients with T2DM inadequately controlled with metformin immediate release (IR) and diet/exercise.

After a 2-week placebo run-in, patients are randomized to receive empagliflozin 25 mg once daily (qd) or glimepiride 1—4 mg qd double-blind for 104 weeks, in addition to metformin IR.

Patients who participate in the initial 104-weeks randomization period will be eligible for a 104-week double-blind extension.

The y endpoint is change from ne in HbA1c. ary endpoints are change from ne in body weight, the incidence of confirmed hypoglycemia, and changes in systolic and lic blood pressure. atory endpoints include change from baseline in FPG, the proportion of patients achieving HbA1C <7%, and effects on various biomarkers of _ 60 _ beta-cell function including insulin, C-peptide, HOMA—B and ulin to insulin ratio, first and second phase insulin secretion after a meal tolerance test.

In addition, y, secondary and exploratory endpoints are evaluated in a oup of patients with Latent Autoimmune Diabetes in Adulthood (LADA), identified by the presence at baseline of autoantibodies against insulin, islet cell cytoplasm, ic acid decarboxylase 65 or the intracytoplasmic domain of the tyrosine phosphatase-like protein lA-2.

Example 8: Effect of empagliflozin arterial stiffness Blood re, arterial stiffness, heart rate variability (HRV) and circulating adrenergic mediators were measured during clamped euglycemia and hyperglycemia in 40 normotensive patients with T1D. Studies were ed after 8 weeks of empagliflozin (25 mg .

Augmentation index (Alx) for the radial and carotid arteries as well as a derived aortic AIX and carotid, radial and femoral pulse wave velocities (PWV) are measured for assessment of arterial stiffness using a oCor® System (AtCor Medical Inc, Itasca, IL).

During clamped euglycemic ions, empagliflozin reduced systolic blood pressure (111i9 to 109i9 mmHg, p=0.0187), and augmentation indices at the radial (-52i16 to -57i17%, p<0.0001), carotid (+1.3i17.0 to -5.7i17.0%, p<0.0001) and aortic ons (+0.1i13.4 to - 6.2i14.3%, 01) declined. Similar effects on al stiffness were observed during clamped hyperglycemia; however, blood pressure effects were not significant. Carotid-radial pulse wave velocity decreased significantly under both glycemic conditions (pS0.0001), while declines in carotid-femoral pulse wave velocity were only significant during clamped hyperglycemia (5.7i1.1 to 9 m/s, p=0.0017). HRV, plasma noradrenaline and adrenaline remained unchanged under both glycemic conditions.

This shows that empagliflozin reduces al stiffness in patients with uncomplicated T1 D.

Example of Pharmaceutical ition and Dosage Form The following example of solid pharmaceutical compositions and dosage forms for oral administration serves to illustrate the present invention more fully without restricting it to the contents of the example. Further examples of compositions and dosage forms for oral administration, are described in . The term "active substance" denotes empagliflozin according to this invention, especially its crystalline form as described in and .

Tablets containing 2.5mg, 5mg, 10mg, 25mg, 50mg of active nce 2.5 mg/ 5 mg/ 10 mg/ 25 mg/ 50 mg/ ‘ ctive substance per tablet per tablet per tablet per tablet per tablet et granulation active substance 2.5000 5.000 25.00 50.00 Lactose 40.6250 81.250 113.00 226.00 Monohydrate Microcrystalline 12.5000 25.000 40.00 80.00 Cellulose Hyd roxypropyl 1.8750 3.750 12.00 Cellulose Croscarmellose 1.2500 2.500 . . 8.00 —""Purified Water Dry Adds ---Microcrystalline 3.1250 6.250 10.00 20.00 Cellulose dal silicon 0.3125 0.625 . 1.00 2.00 o. 5'5. o. CD Magnesium stearate--0.3125 0.625 1.00 2.00 —|oE)"g0 2CD 000 125.000 200.00 400.00 Film Coating -- Film coating system --2.5000 4.000 Purified Water mm Total --65.000 129.000 206.00 409.00 Details regarding the manufacture of the s, the active pharmaceutical ingredient, the excipients and the film coating system are described in , in particular in the Examples 5 and 6, which hereby is incorporated herein in its entirety.

Claims (13)

Claims:

1.) Use of empagliflozin in the manufacture of a pharmaceutical composition for ng the risk of a cardiovascular event in a patient with type 2 diabetes mellitus wherein said cardiovascular event is selected from cardiovascular death and heart failure 5 requiring hospitalization.

2.) The use according to any one of claim 1, wherein said patient has or is at risk of a cardiovascular disease.

3.) The use according to claim 1 or 2, wherein the patient has or is at risk of a cardiovascular disease selected from myocardial infarction, stroke, or peripheral arterial 10 occlusive disease.

4.) The use according to any one of claims 1 to 3 wherein the pharmaceutical composition is for treating type 2 diabetes mellitus and reducing the risk of said cardiovascular event in said patient.

5.) The use according to any one of claims 1 to 4, wherein said cardiovascular event 15 is cardiovascular death.

6.) The use according to any one of claims 1 to 4, wherein said cardiovascular event is heart failure requiring hospitalization.

7.) The use according to claim 5, wherein said cardiovascular death is due to fatal myocardial infarction or fatal stroke. 20

8.) The use according to any one of claims 1 to 7, wherein the patient is a patient with type 2 diabetes mellitus with one or more vascular risk factors selected from A), B), C) and D): A) previous or existing vascular disease selected from myocardial infarction, ry artery disease, percutaneous ry intervention, coronary artery by-pass 25 ng, ischemic or hemorrhagic stroke, congestive heart failure, and eral occlusive al disease, B) advanced age >/= 60-70 years, and C) one or more cardiovascular risk factors selected from - advanced type 2 diabetes us > 10 years duration, 30 - ension, (22430938_1):KZA - current daily cigarette smoking, - dyslipidemia, - obesity, - age >/= 40, 5 - lic syndrome, hyperinsulinemia or insulin resistance, and - hyperuricemia, erectile dysfunction, polycystic ovary syndrome, sleep apnea, or family history of vascular disease or cardiomyopathy in first-degree relative; D) one or more of the following: - med history of dial infarction, 10 - unstable angina with documented multivessel coronary disease or positive stress test, - multivessel Percutaneous Coronary Intervention, - multivessel ry Artery By-pass Grafting (CABG), - history of ischemic or hemorrhagic stroke, 15 - peripheral occlusive arterial disease.

9.) The use according to any one of claims 1 to 8, wherein the pharmaceutical composition further comprises one or more other therapeutic substances.

10.) The use according to claim 9, wherein the one or more other therapeutic substances are selected from other abetic substances. 20

11.) The use ing to claim 9, wherein the one or more other therapeutic substances are selected from with metformin, linagliptin or metformin and linagliptin.

12.) The use according to any one of claims 1 to 11, wherein the pharmaceutical composition is ated for adminstration to the patient orally in a total daily amount of 10 mg or 25 mg. 25

13.) The use according to any one of claims 1 to 12, wherein the pharmaceutical ition comprises 10 mg or 25 mg of empagliflozin. Boehringer Ingelheim International GmbH By the Attorneys for the Applicant SPRUSON & FERGUSON 30 Per: (22430938_1):KZA WO 61918